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Abstract: AMP-activated protein kinase (AMPK) is a key regulator of cellular energy balance. In re-
sponse to metabolic stress, it acts to redress energy imbalance through promotion of ATP-generating
catabolic processes and inhibition of ATP-consuming processes, including cell growth and prolifera-
tion. While findings that AMPK was a downstream effector of the tumour suppressor LKB1 indicated
that it might act to repress tumourigenesis, more recent evidence suggests that AMPK can either
suppress or promote cancer, depending on the context. Prior to tumourigenesis AMPK may indeed
restrain aberrant growth, but once a cancer has arisen, AMPK may instead support survival of the
cancer cells by adjusting their rate of growth to match their energy supply, as well as promoting
genome stability. The two isoforms of the AMPK catalytic subunit may have distinct functions in
human cancers, with the AMPK-α1 gene often being amplified, while the AMPK-α2 gene is more
often mutated. The prevalence of metabolic disorders, such as obesity and Type 2 diabetes, has
led to the development of a wide range of AMPK-activating drugs. While these might be useful
as preventative therapeutics in individuals predisposed to cancer, it seems more likely that AMPK
inhibitors, whose development has lagged behind that of activators, would be efficacious for the
treatment of pre-existing cancers.
Keywords: AMP-activated protein kinase; AMPK; biguanides; CaMKK2; cancer; kinase activators;
kinase inhibitors; LKB1; tumour promoters; tumour suppressors
1. Introduction
The AMP-activated protein kinase (AMPK) is the central component of a signaling
pathway that is conserved in essentially all eukaryotes, the exceptions being a few parasites
(e.g., Plasmodium falciparum, the causative agent of malaria) that spend most of their life
cycle living inside other eukaryotic cells, in which case the host cell provides AMPK and
the parasite may therefore have been able to dispense with it [1–3]. AMPK is activated
by various stresses that act via both classical (canonical) and non-classical (non-canonical)
pathways:
1. The canonical pathway is triggered by increases in the cellular ratios of AMP:ATP
and/or ADP:ATP. In most eukaryotes (apart from plants) ATP is generated from
ADP mainly by mitochondrial oxidative metabolism, with a smaller contribution
from glycolysis (although the latter can become more important in proliferating cells
such as tumour cells). The resultant high ratios of ATP:ADP generated by these
catabolic pathways represent a store of energy (analogous to a fully charged battery)
that can be used to drive energy-requiring cellular processes including anabolic
pathways (leading to cell growth) and progress through the cell cycle (leading to
cell proliferation). An increase in the ratio of ADP:ATP indicates that the energy
status of the cell is becoming compromised, and the reaction catalysed by adenylate
kinases (2ADP↔ ATP + AMP) amplifies this into even larger increases in AMP:ATP
ratios [4]. Binding of AMP or ADP to a crucial site on the AMPK γ subunit (where they
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displace ATP) then activates AMPK by a complex mechanism (discussed in Section 2)
involving phosphorylation at a conserved threonine residue on the α subunit (Thr172)
by the upstream kinase and tumour suppressor, LKB1.
2. A non-canonical pathway in which AMPK is activated by glucose starvation (see
Section 3.1). This activation takes place on the surface of the lysosome where AMPK is
regulated in a reciprocal manner with the mammalian target-of-rapamycin complex-1
(mTORC1), a key pathway that promotes cell growth [5]. Although glucose depriva-
tion can cause increases in AMP:ATP and ADP:ATP ratios in cells that are dependent
upon glycolysis, in other cells this lysosomal pathway of AMPK activation can occur
without any changes in these ratios [6].
3. A non-canonical pathway involving activation, by rising intracellular Ca2+, of the
calcium/calmodulin-dependent kinase CaMKK2 which, like LKB1, phosphorylates
Thr172 (see Section 3.2). This pathway is utilized by many hormones that switch on
AMPK.
4. A non-canonical pathway in which AMPK is activated by DNA-damaging treatments
often used in cancer therapy, such as etoposide [7,8] (see Section 3.3). Although the
mechanisms involved in this pathway are not yet completely understood, it seems
possible that it may eventually have a major impact on treatment of cancer using
cytotoxic, DNA-damaging agents (see Section 5.3).
5. A non-canonical pathway (recently reported) in which AMPK is activated by direct
binding of long-chain fatty acyl-CoA esters (see Section 4.3).
The downstream target proteins that are phosphorylated by AMPK are increasingly
well characterized, with over 60 having been validated as direct targets in a recent review [9].
In general, AMPK down-regulates proteins involved in major anabolic pathways (such as
the synthesis of fatty acids, cholesterol, triglycerides, polysaccharides, RNA and proteins),
while up-regulating proteins that promote the major catabolic pathways (such as glucose
uptake and glycolysis, oxidative metabolism and autophagy). As well as directly opposing
anabolic pathways via phosphorylation of metabolic enzymes and transcription factors
involved in these processes, AMPK activation also does so indirectly by antagonizing the
pro-anabolic mTORC1 pathway [5].
The spectrum of targets that are phosphorylated may depend on the subcellular
location at which AMPK activation takes place. Thus, there are already indications for
different targets being modified depending on whether AMPK is activated by the lysosomal
pathway (#2 above) or by the canonical pathway in the cytoplasm (#1 above) [10], while
acetyl-CoA carboxylase (ACC, one of the classical targets [11] that is a widely-used marker
for AMPK activation) is not phosphorylated in response to the DNA damage pathway (#4
above), presumably because ACC is not present within the nucleus [7].
2. AMPK—Structure and Canonical Regulation by Adenine Nucleotides
AMPK occurs universally as heterotrimeric complexes composed of catalytic α sub-
units and regulatory β and γ subunits (Figure 1). In humans and other vertebrates, there
are two genes encoding α subunit isoforms (PRKAA1 and PRKAA2, encoding α1 and
α2), two genes encoding β subunit isoforms (PRKAB1 and PRKAB2, encoding β1 and
β2) and three genes encoding γ subunit isoforms (PRKAG1, PRKAG2, and PRKAG3, en-
coding γ1, γ2, and γ3). All combinations of α, β and γ isoforms appear to be able to
form complexes [12], generating an array of 12 different heterotrimers whose diversity
may be further increased by splice variants, use of alternative translation start sites, or
post-translational modifications.
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Figure 1. Domain maps of the three subunits of the AMPK heterotrimer: α, β and γ. Each subunit occurs as multiple 
isoforms. “Myr-N” refers to the myristoylated N-terminus of the β subunits. Other abbreviations/acronyms are defined in 
the text. 
As discussed in Section 1, AMPK is normally only significantly active when phos-
phorylated at a conserved threonine residue in the catalytic α subunit that is usually re-
ferred to as Thr172 (this numbering is derived from its position in the rat α2 subunit where 
it was first identified [13], although the exact numbering may vary in different species and 
isoforms). The canonical pathway of activation involves three distinct mechanisms, all of 
which are promoted by binding of AMP to the γ subunit (Figure 2): (i) promotion of 
Thr172 phosphorylation by the upstream kinase, LKB1; (ii) inhibition of Thr172 
dephosphorylation by protein phosphatases; (iii) allosteric activation of AMPK already 
phosphorylated on Thr172 (note that with γ3 complexes this last effect is very small [14]). 
Of these three mechanisms, (ii) is mimicked by binding of ADP [15], although with γ1 and 
γ3 complexes only at 10-fold higher concentrations than AMP (with γ2 complexes, the 
effects of AMP and ADP are similar) [14]. There is general agreement that mechanism (iii) 
is only caused by binding of AMP, but with respect to mechanism (i) the situation is less 
clear. Although it has been reported that the binding of AMP or ADP promotes Thr172 
phosphorylation [16,17], this may only occur significantly with γ1 complexes and then, 
for ADP, only at concentrations likely to be above the normal physiological range [14]. 
The canonical mechanism requires the presence of an upstream kinase that is consti-
tutively active to provide a constant potential for phosphorylation of Thr172 that is, how-
ever, promoted by binding of AMP to the substrate, AMPK. In 2003–2004, three groups 
reported [18–20] that this upstream kinase was LKB1, a kinase that occurs as heterotri-
meric complexes with STRAD and MO25 (both of which occur as α and -β isoforms) [18]. 
STRAD-α or -β, without which LKB1 is completely inactive, is a “pseudokinase” (contain-
ing a domain related to a protein kinase domain but which has no catalytic activity), while 
MO25, whose binding appears to stabilize the LKB1:STRAD complex, is a scaffold protein 
containing helical repeats related to those of Armadillo repeat proteins [21]. The finding 
that LKB1 was an upstream kinase for AMPK was exciting, because LKB1 was known 
from genetic studies to be a tumour suppressor [22], and this introduced the first clear 
link between AMPK and cancer, which is addressed further in Section 5 below. Consistent 
with LKB1 being a tumour suppressor, many human cancer cell lines carry loss-of-func-
tion mutations in the STK11 gene that encodes it. This includes HeLa cells, the first human 
Figure 1. Domain maps of the three subunits of the AMPK heterotrimer: α, β and γ. Each subunit
occurs as multiple isoforms. “Myr-N” refers to the myristoylated N-terminus of the β subunits.
Other abbreviations/acronyms are defined in the text.
As discussed in Section 1, AMPK is normally only significantly active when phospho-
rylated at a conserved threonine residue in the catalytic α subunit that is usually referred
to as Thr172 (this numbering is derived from its position in the rat α2 subunit where it
was first identified [13], although the exact numbering may vary in different species and
isoforms). The canonical pathway of activation involves three distinct mechanisms, all of
which are promoted by binding of AMP to the γ subunit (Figure 2): (i) promotion of Thr172
phosphorylation by the upstream kinase, LKB1; (ii) inhibition of Thr172 dephosphorylation
by protein phosphatases; (iii) allosteric activation of AMPK already phosphorylated on
Thr172 (note that with γ3 complexes this last effect is very small [14]). Of these three mecha-
nisms, (ii) is mimicked by binding of ADP [15], although with γ1 and γ3 complexes only at
10-fold higher concentrations than AMP (with γ2 complexes, the effects of AMP and ADP
are similar) [14]. There is general agreement that mechanism (iii) is only caused by binding
of AMP, but with respect to mechanism (i) the situation is less clear. Although it has been
reported that the binding of AMP or ADP promotes Thr172 phosphorylation [16,17], this
may only occur significantly with γ1 complexes and then, for ADP, only at concentrations
likely to be above the normal physiological range [14].
The canonical mechanism requires the presence of an upstream kinase that is con-
stitutively active to provide a constant potential for phosphorylation of Thr172 that is,
however, promoted by binding of AMP to the substrate, AMPK. In 2003–2004, three groups
reported [18–20] that this upstream kinase was LKB1, a kinase that occurs as heterotrimeric
complexes with STRAD and MO25 (both of which occur as α and -β isoforms) [18]. STRAD-
α or -β, without which LKB1 is completely inactive, is a “pseudokinase” (containing a
domain related to a protein kinase domain but which has no catalytic activity), while
MO25, whose binding appears to stabilize the LKB1:STRAD complex, is a scaffold protein
containing helical repeats related to those of Armadillo repeat protei s [21]. The finding
that LKB1 was an upstream kinase for AMPK was exciting, because LKB1 was known
from genetic studies to be a tumour suppressor [22], and this introduced the first clear
link between AMPK and cance , which is addressed further in Section 5 below. Consistent
with LKB1 being a tumour uppr ssor, any h man cancer cell lines carry l ss-of-function
mutatio s in h STK11 gene that encodes it. This inclu es HeLa cells, the first human
cells ever to be established in culture, which were derived from a case of c rvical cancer
in which analysis of the original tumour biopsies revealed a large deletion in the STK11
gene [23]. Indeed, studies with HeLa cells show that agents that usually activate AMPK
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via the canonical mechanism fail to do so unless LKB1 is re-introduced, due to the lack of
an upstream kinase providing a constant phosphorylation of Thr172 [18–20].
Although several candidates have been proposed (e.g., [24–26]), there is no general
consensus as to the identity of the protein phosphatase(s) that dephosphorylate Thr172.
In any case, since the effect of AMP on Thr172 dephosphorylation is due to its binding to
the substrate (i.e., AMPK) rather than to the enzyme (i.e., the protein phosphatase) [24],
the identity of the latter may not be critical.
We will now briefly discuss the functions of the individual subunits and domains of
AMPK shown in Figure 1.
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binding of AMP or ADP to AMPK also causes a conformational change that inhibits dephosphory-
lation of Thr172 by protein phosphatases; (3) binding of AMP (but not ADP) causes up to 10-fold 
allosteric activation of AMPK. All three effects of AMP and/or ADP are antagonized by the bind-
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The α subunits (α1 or α2) are the catalytic subunits with kinase domains (α-KD) at 
their N-termini. These are typical Ser/Thr-specific protein kinase domains with small N-
terminal lobes (N-lobes) and larger C-terminal lobes (C-lobes), with the binding site for 
the substrate Mg.ATP2− in the cleft between them. Thr172 is located in the “activation loop” 
of the C-lobe, a region where many protein kinases must be phosphorylated to be active, 
and in which phosphorylation causes a conformational change that creates the docking 
site for the protein substrate, orienting its phosphoacceptor residue in line with the γ-
phosphate of the Mg.ATP2− bound in the catalytic site [27]. The α-KD is followed (Figure 
1) by: (i) the autoinhibitory domain (α-AID); (ii) the α-linker, a flexible linker in an ex-
tended conformation; and (iii) a globular C-terminal domain (α-CTD). The α-AID, which 
contains a small bundle of three α-helices, is so-called because constructs containing just 
an α-KD and an α-AID are around 10-fold less active than those containing an α-KD alone. 
In the former constructs, the α-AID binds to both the N- and C-lobes of the α-KD, holding 
Figure 2. The canonical mechanism of activation of AMPK by adenine nucleotides. The action of
adenine nucleotides on AMPK activity is threefold: (1) AMPK not phosphorylated on Thr172 (left) is
phosphorylated by the LKB1:STRAD:MO25 complex and this reaction, which causes at least 100-fold
activation, is pr moted by the binding of AMP (and perhaps ADP) to AMPK itself; (2) binding of
AMP or ADP to AMPK also causes a onformational change t t inhibits dephosphorylation of
Thr172 by protein phosphatases; (3) binding of AMP (but not ADP) causes up to 10-fold allosteric
activation of AMPK. All three effects of AMP and/or ADP are antagonized by the binding of ATP.
The figures in parentheses next to each form of AMPK are an indication of their approximate relative
kinase activity.
2.1. α Subunits
The α subunits (α1 or α2) are t e c tal tic s b nits ith i ase o ains ( - ) at
their N-termini. These are typical Ser/Thr-spe ific protein kinase domains with small
N-terminal lobes (N-lobes) and larger C-terminal lobes (C-lobes), with the binding site for
the substrate Mg.ATP2− in the cleft between them. Thr172 is located in the “activation
loop” of th C-lobe, a region where many protein kina es must be phosphorylated o be
active, and in whic phosphorylation causes a conformational change tha creates the
docking site f r the protein substrate, orienting its phos hoacceptor residue in line with
t e γ-phosphate of the Mg.ATP2− bound in the catalytic site [27]. The α-KD is followed
(Figure 1) by: (i) the aut inhibitory domain (α-AID); (ii) th α-linker, a flexible linker in
a extended conf rm tion; and (iii) a globular C-termin l domain (α-CTD). The α-AID,
which contains a small bundle of thr e α-helices, is so-called b cause constructs containing
just an α-KD and an α-AID are around 10-fold less active than those cont ining an α-KD
alone. In the f rmer constructs, the α-AID binds to both the N- and C-lobes of the α-KD,
holding the latter in a less active conformation [28,29]. In heterotrimers crystallized in
active conformations, the α-linker binds to one surface of the γ subunit where it contacts
the activating ligand, AMP, bound in the crucial CBS3 site (see Section 2.3 below) [30].
This anchoring of the α-linker to the γ subunit by AMP requires a rotation of the α-AID
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away from its inhibitory site behind the kinase domain, thus explaining allosteric activation
by AMP.
In the active forms of the AMPK heterotrimer that have been crystallized, the phospho-
rylated Thr172 residue is partly buried in a cleft between the α-KD and the α- and β-CTDs,
where it is likely to be sterically protected against dephosphorylation. The conformational
change that occurs when ATP replaces AMP at CBS3 (although not well understood)
appears to make Thr172 more exposed to protein phosphatases, thus explaining how
AMP binding protects Thr172 against dephosphorylation. How AMP binding promotes
phosphorylation of Thr172 by LKB1 is less clear.
The C-terminal domains of the α subunits from vertebrates (and Caenorhabditis elegans)
contain, just prior to their final α-helix, a serine/threonine-rich loop of around 50 residues
that is not present in the α subunits from fungi, plants and insects. This region, which
has been termed the “ST loop” (Figure 1), appears to be phosphorylated at multiple sites
by multiple kinases [31–35], and our group have proposed that it represents a regulatory
sequence that has been inserted during evolution of the animal kingdom [3,35]. This loop
is not resolved in any of the crystal structures of AMPK heterotrimers, either because it
has been deleted from the constructs used, or because it was mobile within the crystals.
However, our group have provided evidence that when AMPK-α1 is phosphorylated at Ser-
487 within the ST loop by the protein kinase AKT, the loop interacts with the small lobe of
the kinase domain to block phosphorylation of Thr172 [35]. This provides a mechanism by
which the anabolic hormones insulin and IGF-1, which activate AKT, can oppose activation
of pro-catabolic and anti-anabolic signalling by AMPK [31,35].
Following the ST loop, the final α-helix of the α-CTDs from both α1 and α2 contain
well-defined nuclear export sequences (NES) (Figure 1) [36]. There is good evidence that
complexes containing the α2 isoform are enriched in the nuclei of several cell types [37–40],
although it is also clear that α1-containing complexes can be present in the nucleus [7].
However, the presumed nuclear localization sequences (NLS) that promote nuclear entry
of α1- and α2-containing complexes remain to be fully identified. The α2 isoform does
contain a cluster of basic residues in the C-lobe of the α-KD (only partially conserved in
α1) that was claimed to function as an NLS [41], but these results were not confirmed by
others [36].
2.2. β Subunits
The β subunits of AMPK (β1 or β2) contain consensus sequences for myristoylation
(the covalent attachment of a C14 saturated fatty acid) at their N-termini, and the human
β1 and β2 subunits are indeed both modified in this manner [17,42]. N-myristoylation is
thought to be required for attachment of AMPK to membranes [17,42], particularly to the
cytoplasmic surface of the lysosome [6]. The exact proportion of AMPK that is bound to
membranes, and whether there is a “myristoyl switch” mechanism that modulates this
attachment, as with other myristoylated proteins [43], remains unclear at present. The
remainder of the N-terminal regions of the β1 and β2 subunits are less well conserved
and their functions unknown, but there are conserved domains in the centre and at the
C-termini (Figure 1). The central domain is a carbohydrate-binding module (β-CBM)
similar to those found in enzymes that metabolize starch, glycogen or related polysaccha-
rides [44]. The β-CBM causes a proportion of AMPK within the cell to bind to glycogen
particles [45,46], and the glycogen-binding site, containing two conserved tryptophan
residues, is well-defined [47]. Glycogen binding would cause co-localization of AMPK
with glycogen-bound substrates such as: (i) glycogen synthases [48,49], key enzymes of
glycogen synthesis that are inactivated by AMPK; (ii) R5/PTG/PPP1R3C [50], a protein
phosphatase-1 regulatory subunit that targets the catalytic subunits to glycogen; and (iii)
genethonin-1/STBD1 [51], which is involved in glycogen degradation by the lysosome.
Surprisingly, knock-in mutations in mice that abolished glycogen binding in vivo, by
mutation of key tryptophan residues in AMPK-β1 or -β2, did not reveal any significant
changes in glycogen content in liver or muscle, although other metabolic defects were
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observed [52]. Notably, the β1 W100A mice showed increased fat content in liver (where
β1 is the predominant isoform), while the β2 W98A mice showed increased fat content in
skeletal muscle (where β2 is the predominant isoform) as well as increased overall fat mass.
These changes were associated with reduced expression of AMPK-α and -β1 in the liver
of β1 W100A mice, and of AMPK-α and -β2 in the muscle of β2 W98A mice; both effects
were associated with reduced total AMPK activity. The authors suggested that the binding
of AMPK to glycogen provides a reserve pool of the kinase more resistant to degradation,
that would potentially become available to phosphorylate non-glycogen bound targets
when glycogen stores became degraded [52]. If this interesting proposal is correct, AMPK
can be regarded as a type of “glycogen-sensor”.
2.3. γ Subunits
The γ2 and γ3 isoforms contain lengthy N-terminal regions that are unrelated to
each other and are not present in the γ1 isoform; although their exact functions are not
known, they may be involved in targeting the complexes to specific subcellular locations,
particularly in striated muscles that express high levels of either γ2 (cardiac muscle) or
γ3 (skeletal muscle). All three γ subunits also contain four tandem repeats (Figure 1) of
a sequence of around 60 residues termed a CBS repeat [53]. CBS repeats occur in about
50 proteins encoded in the human genome, and also occur in bacteria and archaea [54].
They almost invariably occur as tandem repeats, and the two repeats of single pairs have
been shown to associate together to form pseudodimers, with two pseudosymmetrical
binding sites for potential ligands in the intervening cleft [54]. The ligands known to bind
there usually contain adenosine, and include ATP, AMP and S-adenosyl methionine [54,55].
The AMPK-γ subunits are unusual in having four repeats, labelled CBS1 through CBS4
(Figure 1). The two pseudodimers formed by CBS1:CBS2 and CBS3:CBS4 come together
head-to-head to form a disc-shaped structure with one repeat in each quadrant, containing
four potential nucleotide-binding sites lining a narrow aqueous channel through the centre.
These binding sites are now numbered [56] according to the number of the CBS repeat
that binds the adenosine moiety of the bound nucleotide (the phosphate group(s) can bind
to side chains from other repeats). Of these, the CBS1 site may be permanently occupied
by ATP [57], the CBS2 site appears to be always unused, while the CBS4 site (confusingly,
originally called site 3 [58]) appears to be permanently occupied by AMP [58]. This leaves
CBS3 as the critical site which, when occupied by AMP in the active form of the kinase,
contacts the α-linker (Section 2.1). Displacement of AMP by ATP at the CBS3 site is thought
to convert the kinase to a less active conformation that is also more susceptible to Thr172
dephosphorylation. The functions of the CBS1 and CBS4 sites are less clear, although it has
been proposed that their permanent occupancy by ATP and AMP (respectively) may alter
the conformation of the CBS3 site such as to increase its affinity for AMP relative to ADP or
ATP [57]. This helps to explain how AMPK achieves the difficult task of sensing changes in
AMP in the presence of much higher concentrations of ADP and ATP. An additional factor
in this discrimination between nucleotides is that the CBS sites preferentially bind free ATP
rather than its complex with Mg2+, in which some of the favourable interactions between
the negatively-charged phosphate groups of ATP and the positively-charged basic side
chains of the CBS sites would be sterically blocked by the Mg2+ ion; note that only a small
proportion of cellular ATP (around 10%) normally occurs as the Mg2+-free form.
3. Non-Canonical Regulation of AMPK
3.1. Non-Canonical Regulation by Glucose Starvation
Since it was first demonstrated in 1998 [59], glucose starvation of mammalian cells
has been widely used as a treatment to activate AMPK. Most researchers seem to have
assumed that the effect is caused by a reduced input of glucose into glycolysis, leading
to ATP depletion and consequent activation by the canonical pathway. While this can
indeed occur in some cell types that are dependent on glycolysis for ATP production,
in other cells (e.g., mouse embryo fibroblasts) removal of glucose from the medium still
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activates AMPK without any associated increases in AMP:ATP or ADP:ATP ratios, as long
as alternative carbon sources such as glutamine and pyruvate are present in the medium [6].
Even in those cells where there are increases in AMP:ATP and ADP:ATP ratios triggered by
glucose starvation (e.g., HEK-293 cells), AMP-insensitive mutants of AMPK (which carry a
mutation in the crucial CBS3 site on the γ subunit) can still be activated by the treatment [6].
Thus, it is clear that, in many cells, there is an adenine nucleotide-independent component
of the mechanism by which AMPK is activated during glucose starvation. In such cases,
activation is thought to occur via a complex mechanism (Figure 3) involving the direct
sensing of the glycolytic intermediate fructose-1,6-bisphosphate (FBP) by FBP aldolase,
and the recruitment of AMPK to a “super-complex” on the lysosomal membrane involving
the vacuolar-ATPase, the Ragulator complex, Axin, LKB1, and AMPK [3].
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glycolytic intermediate fructose-1,6-bisphosphatase (FBP), bound to it. This causes the opening of
TRPV Ca2+ channels located at ER:lysosome contact sites, maintaining the function of the v-ATPase
and promoting mTORC1 activity via the Ragulator complex, which is anchored on the surface of
the lysosome via lipid modifications. When glucose is absent or limiting (lower panel), aldolase will
not be fully occupied by FBP, and it interacts with and inhibits the neighbouring TRPV channels.
The v-ATPase is now inhibited, allowing an interaction between the Ragulator and the cytoplasmic
Axin:LKB1 complex, and bringing LKB1 into the proximity of AMPK, which is then phosphorylated
and activated. In this version of the m del, a po l of AMPK is viewed as being permanently located
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Sensing of carbohydrate availability may have been one of the ancestral roles of the
AMPK system, since the orthologue in budding yeast is potently activated by glucose
removal from the medium [61,62]. Similarly, the orthologues in green plants are required
for responses to darkness [63,64], which blocks the supply of carbohydrate from the Calvin
cycle of photosynthesis. Nevertheless, the non-canonical pathway for glucose sensing
cannot be completely conserved between mammals and yeast, because there appear to be
no orthologues of Axin in the latter. In addition, neither the yeast [62] nor the plant [65]
orthologues of AMPK are allosterically activated by AMP, although there is evidence that
their dephosphorylation at the residue equivalent to Thr172 is inhibited by binding of
ADP [66] or AMP [67], respectively. Thus, even the canonical pathway is not completely
conserved across all eukaryotes.
Int. J. Mol. Sci. 2021, 22, 186 8 of 30
3.2. Non-Canonical Regulation by CaMKK2
Although the basal phosphorylation of Thr172 is very low in HeLa cells (which lack
LKB1), it is not eliminated completely and can be promoted by agents that increase in-
tracellular Ca2+ [68]. This suggested the existence of an alternative upstream kinase to
LKB1 in these cells that was activated by Ca2+. This was soon traced to phosphoryla-
tion of Thr172 by the Ca2+/calmodulin-dependent kinase, CaMKK2 [68–70], which had
originally been identified as an upstream kinase for another Ca2+/calmodulin-dependent
kinase, CaMKI [71]. The Ca2+ → CaMKK2 → AMPK pathway occurs, for example, as
a response to hormones and agonists sensed by G protein-coupled receptors and other
receptor types that are coupled to release of inositol-1,4,5-trisphosphate (IP3) from the
plasma membrane, which in turn triggers release of Ca2+ from the endoplasmic reticulum
(Figure 4). Such agonists include: in endothelial cells, thrombin acting at protease-activated
receptors and vascular endothelial cell growth factor acting at VEGF receptors [72,73]; and,
in specific neurons of the hypothalamus, the “hunger hormone” ghrelin acting at GHSR1
receptors [74]. The last effect is important in promotion of appetite during fasting [75].
It is intriguing that a signalling pathway that may have evolved to sense carbohydrate
deficiency at the single cell level (see Section 3.1) should have become adapted to fulfill a
similar role at the whole-body level in mammals, where feeding is now a complex behavior
involving multiple hormonal stimuli.
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Figure 4. Non-canonical mechanism of activation of AMPK by hormones that trigge intracellu-
l r Ca2+ release. Hormones such as ghrelin bind t a G prot in-cou led receptor (GPCR) that
is coupled via G pr teins containing Gαq/11 to activation of phosphatidylinositol-specific phos-
pholipase C (PI-PLC). This triggers release of inositol-1,4,5-trisphosphate (IP3) from the plasma
membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 diffuses to the endoplas-
mic reticulum where it binds to IP3 receptors, triggering release of Ca2+ ions. These in turn activate
Ca2+/calmodulin-dependent kinase kinase-2 (CaMKK2) which phosphorylates AMPK at Thr172,
causing its activation.
3.3. Non-Canonical Regulation by DNA Damage
In 2008 it was reported that AMPK was activated in response to the anti-cancer agent
etoposide [76], and this was later also observed on treatment of cells with hydroxyurea,
aphidicolin, bleomycin or ultraviolet light [8], as well as ionizing radiation [77]. These
treatments either directly cause single or double strand breaks in DNA or are inhibitors
of DNA synthesis that cause stalling of replication forks, which can in turn lead to DNA
strand breaks; several of them are used as cytotoxic therapies in cancer. It was originally
proposed that activation of AMPK by etoposide required the phosphatidylinositol 3-kinase–
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like kinase ATM [78], which is known to be activated by double strand breaks in DNA
and to phosphorylate the upstream kinase for AMPK, LKB1 [79]. However, this cannot
be the primary mechanism, because both etoposide [7,76] and ionizing radiation [77]
still activate AMPK even in LKB1-null tumour cells such as HeLa cells, while AMPK
activation by etoposide was not blocked by the ATM inhibitor KU-55933 [7]. Indeed,
AMPK activation by etoposide or hydroxyurea in LKB1-null cells is mediated by Thr172
phosphorylation catalysed by CaMKK2, and is associated with increases in Ca2+ within the
nucleus (Figure 5) [7,8]. Interestingly, only AMPK complexes containing the α1 isoform are
activated by etoposide, even if α2 is also present in the cells under study [7]; the explanation
for this isoform selectivity is not known at present. Note that even in cells that express
LKB1 (i.e., most normal cells), LKB1 is probably not responsible for phosphorylation and
activation of AMPK within the nucleus, because binding of LKB1 to STRAD and MO25,
which is essential for its activity, also causes its exclusion from the nucleus [80].
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excessive resection at stalled replication forks. As indicated by question marks, several aspects of
this mechanism remain unresolved: (i) how is the DNA damage sensed? (ii) what is the source of
Ca2+ and its mechanism of release into the nucleus? and (iii) how is the translocation of AMPK-α1 to
the nucleus achieved and regulated? The source of nuclear Ca2+ release is shown here as the nuclear
envelope, but this is also unconfirmed.
Intriguingly, activation of AMPK in LKB1-null cells (using the Ca2+ ionophore A23187
to activate CaMKK2) provides significant protection against etoposide-induced cell death,
an effect that was abolished in AMPK knockout cells [7]. Also consistent with this, AMPK
knockout cells are more susceptible to cell death induced by hydroxyurea [8]. Why does
AMPK activation enhance cell survival in response to DNA damage? One reason might
be that AMPK activation using various treatments such as AICA riboside [81], glucose
starvation [82], or activation of the Ca2+/CaMKK2 pathway [7] causes a G1 cell cycle arrest,
thus restricting entry of cells into S phase where they would be more susceptible to DNA
replication stress or DNA damage. This interpretation was supported by findings that the
G1 cyclin-dependent kinase inhibitor, palbociclib, caused a very similar degree of protection
against etoposide-induced cell death as AMPK activation, but only in those cell lines
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where it also caused a G1 arrest [7]. An alternative explanation (not necessarily mutually
exclusive) came with the recent identification by Li et al. [8] of the exonuclease EXO1 as a
direct nuclear target for AMPK. These authors reported that EXO1 became phosphorylated
at Ser746 by AMPK (perhaps also in part by the kinase Chk1) in response to treatment
with hydroxyurea or aphidicolin. This phosphorylation was reported to trigger EXO1
binding to 14-3-3 proteins, preventing its recruitment to chromatin. This would, in turn,
protect against excessive resection of replication forks by EXO1, thus maintaining genome
stability when DNA synthesis was inhibited. Consistent with this, in EXO1 knockout cells
reconstituted with an S746A mutant and treated with the ribonucleotide reductase inhibitor
hydroxyurea, there were elevated levels of fork resection and chromosomal abnormalities,
including chromosome breakage and fusion, compared with wild type controls. Moreover,
the increased sensitivity of AMPK knockout cells to cell death induced by hydroxyurea
could be largely reversed by siRNA knockdown of EXO1 [8].
Taken together, these findings suggest that the activation of AMPK in response to DNA
damage aids cell survival. A corollary of this is that AMPK inhibitors should potentiate the
effects of many of the DNA damaging, cytotoxic treatments that are used in cancer therapy.
This possibility is considered further in Section 5.
4. Pharmacological Activation and Inhibition of AMPK
The idea that activation of AMPK might be useful in treatment of disorders of whole
body energy balance such as obesity and Type 2 diabetes, which appears to have been
first proposed in 1999 [83], led to a drive towards the development of AMPK activators
by pharmaceutical and biotechnology companies. These campaigns have now given rise
to several different classes of activator that are discussed below. There has been much
less emphasis on the development of inhibitors, although (as mentioned in the previous
paragraph) these may now be regarded as good candidates for the treatment of some
cancers. The limited current progress in this direction is discussed in Section 4.4 below.
4.1. AMPK Activators: Pro-Drugs That Are Converted to AMP Analogues
The first pharmacological agent shown to activate AMPK was 5-aminoimidazole-
4-carboxamide ribonucleoside [84–86], which those in the AMPK field often refer to as
AICAR. Unfortunately, this acronym can cause confusion because researchers in the field of
nucleotide metabolism use the same term to refer to the monophosphorylated nucleotide,
also sometimes known as ZMP; to avoid this, we will refer to the nucleoside as AICA
riboside and to the nucleotide as ZMP. The incubation of cells in vitro (or injection of
animals in vivo) with AICA riboside usually leads to activation of AMPK because the
riboside is rapidly taken up into cells by adenosine transporters [87] and rapidly converted
to ZMP by adenosine kinase [88] (Figure 6). ZMP, which is an AMP analogue, then mimics
the multiple effects of AMP on the AMPK system, including allosteric activation and
protection against Thr172 dephosphorylation. Although ZMP is around 50-fold less potent
in these effects than AMP itself, AICA riboside is nevertheless effective at activating AMPK
in many cells because ZMP accumulates to millimolar concentrations in their cytoplasm [86].
AICA riboside was historically used as a means of artificial activation of AMPK in vitro
and in vivo, and is still sometimes used today. However, it is perhaps not surprising that
millimolar levels of any ligand can have off-target effects. For example, ZMP mimics the
effects of AMP on other AMP-sensitive enzymes, including the glycogenolytic enzyme
glycogen phosphorylase in cardiac muscle [89] and the gluconeogenic enzyme fructose-1,6-
bisphosphatase in the liver [90]. Indeed, some of the effects of AICA riboside on hepatic
glucose production, which were originally ascribed to AMPK activation, can now be put
down to inhibition of fructose-1,6-bisphosphatase by ZMP [91,92].
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ZMP is, in fact, a naturally-occurring metabolite in the pathway of de novo purine
nucleotide synthesis, being converted in two further steps to IMP, the common precursor
for AMP and GMP (Figure 6). These two steps are catalysed by the enzymes AICAR
transformylase and IMP cyclohydrolase, which are carried on a single polypeptide chain
encoded by the ATIC gene. The rapid metabolism of ZMP to IMP explains why AMPK
is not activated by AICA riboside in some cell types, especially in proliferating cells that
have a high capacity for de novo nucleotide biosynthesis. ICAR transformylase (note
that ICAR here refers to the nucleotide, i.e., ZMP) uses N10-formyltetrahydrofolate
to add an aldehyde group to what is then converted by IMP cyclohydrolase into the
6-membered ring of IMP. Because of this, AICAR transformylase is inhibited by folate
analogues such as methotrexate and pemetrexed, which are used in the treatment of some
c ncers and autoinflammatory disorders. While the primary target of thes antifolate dr s
is thought to be thymidyl t synt ase and hence DNA synthesis, AICAR tran form lase
may be a secondary targ t. Thus, pemetr xed has been shown to activate AMPK in
leukaemia cells due to inhibition of AICAR transformylas and onsequent accum lation
of its substrate ZMP [93], whil in HEK-293 cells, where AICA riboside has little effect on
its own because f rapid metabolism of ZMP by AICAR transformylase, the ribonucleoside
does activate AMPK dramatically in the presence of the AICAR transformylase inhibitor,
methotrexate [94]. Whether these effects on AMPK explain any of the anti-ca cer actions of
antifolat drugs remains unclear at present.
A much more selective AMPK activator that works through a different pro-drug
mechanism is C13, which contains a phosphonate group esterified on two of its oxygen
atoms (Figure 6). This modification makes C13 cell-permeable but, once inside cells, it
is converted by intracellular esterases into C2, a phosphonate analogue of AMP that,
remarkably, is at least two orders of magnitude more potent as an allosteric activator of
AMPK than AMP itself [95]. An explanation for this surprising finding is that although its
binding site on the AMPK-γ subunit overlaps with that of AMP, the two nucleotides bind
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in different orientations [96]. Another notable feature of C2 is that it is almost completely
selective for AMPK complexes containing the α1 isoform, with little or no effect on α2
complexes. One major advantage of the use of C13, compared with AICA riboside, is that
its active metabolite C2 does not affect the regulation of other AMP-sensitive enzymes such
as glycogen phosphorylase and fructose-1,6-biphosphatase [97].
A final compound that activates AMPK by a pro-drug mechanism related to that of
AICA riboside is cordycepin, also known as 3′-deoxyadenosine (Figure 6). Cordycepin
is an adenosine analog derived from species of the genus Cordyceps, which are parasitic
fungi (highly prized in traditional Chinese medicine) that infect insect larvae such as
caterpillars and (rather gruesomely!) consume them from within [98]. Cordycepin is an
adenosine analogue that is taken up into cells and converted by cellular metabolism into
mono-, di- and tri-phosphates. Since it lacks a hydroxyl group at the 3′-position on the
ribose ring, if cordycepin is incorporated into RNA it will cause chain termination. Poly(A)
polymerases, which add the poly(A) tails to mRNA, seem to accept cordycepin in place
of adenosine particularly readily, so that treatment of cells with cordycepin reduces the
lengths of the poly(A) tails, and hence the stability, of many mRNAs [99]. This may be
the main reason why cordycepin has cytotoxic effects to reduce cell viability. However,
two groups reported in 2010 that cordycepin treatment also activated AMPK [99,100].
Our group has provided evidence that this occurs because cordycepin is taken up into
cells via adenosine transporters, and is converted by adenosine kinase into cordycepin
monophosphate (Figure 6), which then mimics the multiple effects of AMP to activate
AMPK [88]. Cells lacking AMPK are also more sensitive to the cytotoxic effects of cordy-
cepin, suggesting that the ability of the compound to activate AMPK normally ameliorates
its cytotoxic effects.
4.2. AMPK Activators: Indirect Activation via Inhibition of ATP Synthesis
Since the inhibition of ATP synthesis will cause increases in the ADP:ATP ratio that
are amplified by adenylate kinases into even larger increases in the AMP:ATP ratio, this
will inevitably also cause a secondary, indirect activation of AMPK (Figure 7). For example,
in cells that are partly reliant on glycolysis for ATP production, addition of the glycolytic
inhibitor 2-deoxyglucose causes rapid AMPK activation [101]. However, the major genera-
tor of ATP in most animal cells is not glycolysis but mitochondrial oxidative metabolism,
and many pharmacological agents that activate AMPK do so indirectly by inhibiting the
latter (Figure 7). In particular, Complex I of the respiratory chain (NADH–ubiquinone
oxidoreductase) is a remarkable membrane-bound multiprotein machine with 14 core
subunits and around 30 accessory subunits [102]. It is perhaps not surprising that many
xenobiotic compounds that are hydrophobic in nature should find binding sites within
this complex, where they cause its inhibition, with consequent downstream activation of
AMPK. Many compounds known to activate AMPK by this mechanism are secondary
products of plants and may be produced by the plant to poison herbivorous insects and
other animals, and thus deter grazing. These compounds are often stored in the cell wall
or vacuole of the producing plant cell, where they will not come into contact with the
mitochondria of the plant itself [103]. An example of a natural plant product that activates
AMPK is galegine [104], which is derived from the plant Galega officinalis. The latter (also
known as Goat’s Rue, presumably because it is poisonous to goats!) was recommended as a
herbal remedy in a medical text [105] published as long ago as 1640 by John Parkinson, the
court physician to King James I of England. Galegine itself, an isoprenyl guanidine, turned
out to be too toxic for human use, but in the 20th century various biguanide derivatives,
including metformin and phenformin, were synthesized. In the second half of the century
these became mainstays of the treatment of Type 2 diabetes, although phenformin was with-
drawn in the late 1970s because in rare cases it was associated with a life-threatening lactic
acidosis. In 2000, two groups reported that metformin and phenformin were inhibitors of
Complex I of the respiratory chain [106,107] (providing, incidentally, an explanation for
the lactic acidosis associated with phenformin use), and the following year it was reported
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that metformin activated AMPK [108]. Although there have been various proposals to
explain the mechanism of action of biguanides other than by inhibition of Complex I and
other than by AMPK activation [109,110], there is general agreement that these drugs do
indirectly activate AMPK.
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Figure 7. Indirect activation of AMPK by drugs that interfere with cellular ATP synthesis. Depending
on the cell type, drugs that inhibit glycolysis (e.g., 2-deoxyglucose) or that inhibit mitochondrial
xi ative phosphorylation (especially Complex I inhibitors such as metformin, phenformin and
berberine) caus an accumulation of ADP relative to ATP. This in turn ca ses displacement of the
adenylate kinase reaction towards AMP and TP, increasing AMP dramatically while having much
smaller effects on ADP and ATP levels. The increase in AMP (and perhaps also ADP) relative to ATP
then activates AMPK by the canonical mechanism shown in Figure 2.
Traditional herbal medicines are a particularly rich source of natural plant products
that activate AMPK—a 2016 review listed at least 100 such compounds [111], and more
are still being reported in multiple apers every week. In most case , the mechani m(s)
by which these compounds activate AMPK have not been established. However, berber-
ine [112] and arctigenin [113] have been shown to inhibit Complex I of the respiratory chain
while galegine, quercetin, resveratrol, berbamine, and mangiferin have all been suggested
to activate AMPK indirectly by altering cellular adenine nucleotide ratios [114–116].
4.3. AMPK Activators: Drugs and Metabolites Binding at the AdaM Site
Several pharmaceutical companies have isolated direct activators of AMPK from
compound libraries via high-throughput screens that searched for allosteric activators of
the purified kinase (Figure 8). First-in-class was A-769662, which had favourable effects
on several metabolic parameters when injected into genetically obese (ob/ob) mice, but
had poor oral availability [117]. Mechanistic studies suggested that although A-769662
binding had similar effects to AMP (causing both allosteric activation and inhibition of
Thr172 dephosphorylation) it bound at different site(s), and the interactions appeared to
involve the β subunit because mutations in the latter abolished activation by A-769662
but not AMP [118,119]. Also supporting a role for the β subunit were findings that
A-769662 only activated AMPK complexes containing β1 and not the β2 isoform [120].
Additional screens led to the development of more potent activators in this class, such as
MT 63-78 [121], PF-06409577 [122], PF-249 [123], PF-739 [124], and MK-8722 [12] (Figure 8).
Several of these compounds have much better oral availability than A-769662 and some,
e.g., PF-739 [124], and MK-8722 [12], are termed “pan-β” activators in that they activate
β2-containing complexes almost as well as β1 complexes. Because β2 is the major β subunit
isoform expressed in skeletal muscle, both PF-739 and MK-8722 are effective in promoting
glucose uptake by skeletal muscle, and this appears to be why they are more efficacious
in ameliorating metabolic defects in animal models of obesity and Type 2 diabetes than
β1-selective activators, such as A-769662 or PF-249 [12,124].
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The crystallization of human AMPK complexes with 991 (a lead compound identi-
fied during development of MK-8722), or A-769662 or its halogenated analogues, finally
definitively identified the binding site for these compounds [30,125]. They bind in a deep
hydrophobic cleft located between the β-CBM (the opposite surface to the glycogen-binding
site) and the N-lobe of the α-KD (the opposite surface to the MgATP2--binding site). Be-
cause this site lies between the α and β subunits of the complex, it is unique to AMPK, and
therefore a potentially specific target site for therapeutics. A curious feature of this site is
that essentially all of the compounds that were initially found to activate AMPK by binding
to it were derived from libraries of synthetic small molecules, rather than natural products.
However, most researchers in the field believe these comp unds must be mimicking a
metabolite that occurs naturally in mammalian cells, h nce its designation as the allosteric
dru nd metabolite (ADaM) si e [126]. One natur l product that does bi d the ADaM
site is salicylate, an active metabolite of the drug acetyl s icylic acid (ASA or aspirin).
Salicyla , or derivatives su h as salicin and me yl salicylate, are used by higher plants as
hormones th t signal infection by pathogens [127]. Salicylate was found to activate AMPK
in a manne compe itive with A-769662 [128], and an iodinated analogue of salicylate bound
to the same site as A-769662 [125]. Ho ever, salicylate would not occur turally in animals,
ex ept perhaps if plant suffering from a pathogen infection had been ingested.
Rece tly, it has been suggested by Pinkosky t al. [129] that the natural ligands that
activate AMPK by binding to the ADaM site may be long-chain fatty acyl-CoA esters
(LCFA-CoAs). Ironically, this brings the st ry of regulation of AMPK full circle, as one
of the first papers to efine AMPK and demonstrate its sensitivity to AMP also noted
that its activation by an upstream kinase (at that time unidentified) was enhanced by
palmitoyl-CoA [130]. Subsequently, activation of AMPK by LCFAs was found in perfused
rat heart in vitro and in rat liver in vivo [131,132], and it was also reported that CoA esters
of LCFAs or LCFA analogues enhanced phosphorylation of AMPK by LKB1 [133,134].
In this latest paper [129], the structural basis for the regulation of AMPK by LCFAs has
been addressed. It was found that micromolar concentrations of LCFA-CoAs containing
saturated or mono-unsaturated fatty acids of 12 carbons or more activated AMPK, whereas
the corresponding free acids or carnitine esters did not. Moreover, like A-769662, palmitoyl-
CoA (C16, saturated) only activated β1-containing complexes, and β-CBM mutations that
perturbed the ADaM site, but not γ subunit mutations affecting the nucleotide-binding sites,
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eliminated or reduced palmitoyl-CoA-induced AMPK activation. Note that, in cells subject
to glucose starvation, LCFA oxidation in mitochondria would represent a crucial alternative
source of ATP. The activation of AMPK by LCFA-CoAs, derived either from external sources
or from breakdown of stored triglycerides, would therefore represent a type of “feed-
forward” activation that would trigger enhanced LCFA oxidation via phosphorylation of
acetyl-CoA carboxylases (ACC1/ACC2), with consequent relief of malonyl-CoA-mediated
inhibition of LCFA uptake into mitochondria by the carnitine:palmitoyl-CoA transferase
system [135]. Consistent with this, Pinkosky et al. [129] found that incubation of mouse
hepatocytes with LCFAs promoted phosphorylation of ACC1/ACC2 at the equivalent
AMPK sites (S79/S221), while oral administration of a triglyceride and phospholipid
emulsion in vivo promoted fat oxidation in wild type mice, but not in knock-in mice in
which both S79 and S221 had been mutated to alanine. If this intriguing model is correct,
AMPK represents not only a sensor of cellular energy status and an indirect sensor of the
availability of glucose (and perhaps also glycogen, see Section 2.2), but also a direct sensor
of fatty acid availability.
4.4. AMPK Inhibitors
Perhaps because the suggestion that inhibitors of AMPK might be useful in the
treatment of cancer has only been made fairly recently (see Section 5.3 below), there
has been much less progress in their development than for AMPK activators. In 2001,
a screen identified compound C as an inhibitor of AMPK that appeared to bind to the
MgATP2--binding site in the kinase domain [108]. It did not inhibit any of a panel of
other protein kinases [108] and, as a result, is still often claimed to be a “highly selective”
inhibitor of AMPK. However, this is not the case; one early indication that compound C
has multiple targets was that it is identical with dorsomorphin, which was identified in an
independent screen for compounds that perturb dorsoventral axis formation in zebrafish
and is an inhibitor of BMP (bone morphogenetic protein) signalling acting independently of
AMPK [136]. Moreover, in a screen of around 70 protein kinases, Bain et al. [137] reported
that at least ten were inhibited by compound C to a greater extent than AMPK, while in
recent screens of more than 100 protein kinases available via the MRC Kinase Profiling
Inhibitor Database [138], up to 30 were inhibited to a greater extent than AMPK. As stated
by Bain et al. [137]: “the use of this compound to identify potential functions of AMPK is
not recommended”. The field therefore awaits the development of a truly specific inhibitor
and, despite the widespread use of compound C as an AMPK inhibitor in the literature,
currently the only way to be sure that AMPK is involved in a cellular process is to use
genetic approaches such as gene knockouts.
5. Is AMPK a Tumour Suppressor or a Tumour Promoter?
The discovery that AMPK represented a major signalling pathway downstream of
LKB1 [18–20] immediately suggested that it might mediate some of the tumour suppressor
effects of LKB1. The gene encoding LKB1 in humans (STK11) had been shown a few
years earlier to be the primary gene mutated in Peutz–Jeghers syndrome, a hereditary
predisposition to cancer [139]. Patients with this syndrome are usually heterozygous
for loss-of-function mutations in STK11 and suffer from the growth of numerous polyps
in the intestine. These are classed as hamartomas and are usually benign, but frequent
surgery may be required to correct them, and individuals with the syndrome also carry
a greatly increased risk of malignant tumours occurring at many different locations [22].
In addition, somatic mutations in STK11 are now known to occur quite frequently in
non-inherited cancers. For example, the gene is mutated in 10–20% of all cases of human
lung cancer [1,140–142].
It is worth noting that LKB1 is also an upstream kinase for a family of twelve protein
kinases known as the AMPK-related kinases or ARKs. These are related to AMPK within
their kinase domains and have critical threonine residues equivalent to Thr172 of AMPK
within their highly conserved activation loop sequences [143,144]. In principle, any one of
Int. J. Mol. Sci. 2021, 22, 186 16 of 30
these ARKs could exert tumour suppressor effects of LKB1, and indeed there is evidence
that two of them, MARK1 and MARK4, are involved in the epithelial-to-mesenchymal
transition, which is important in tumour metastasis [145]. However, AMPK-α1 and -α2 are
the only members of this family for which where there is clear evidence that they cause
inhibition of cell growth and cell proliferation when activated, and these are characteristics
expected for tumour suppressors.
5.1. Evidence from Mouse Models That AMPK Is a Tumour Suppressor
Strong evidence that AMPK can act as a tumour suppressor came from genetic manip-
ulation of certain mouse models, particularly of B- and T-cell lymphomas. Analysis of these
cancers has the advantage that cells of the haemopoietic lineage only express the α1 and not
the α2 isoform of the AMPK catalytic subunit, so that to study the effect of lack of AMPK
it is only necessary to knock out one gene (Prkaa1) rather than two. Initial results came
from the study of B cell lymphomas induced by over-expression of the Myc oncogene from
a B-cell-specific promoter [146]. Consistent with AMPK-α1 being a tumour suppressor,
loss of both alleles of Prkaa1 caused a notable acceleration in the onset of lymphomas,
while loss of a single allele caused an intermediate effect. Studies with lymphoma cells
over-expressing Myc in vitro also revealed that knockdown of AMPK-α1 using shRNA
was associated with a hyperactivation of the mTORC1 pathway, which was to be expected
since AMPK is known to restrain mTORC1 activity via multiple mechanisms [5]. This in
turn led to increased glucose uptake and flux through the glycolytic pathway to provide
precursors for biosynthesis—an example of the well-known Warburg effect that is often
displayed by tumour cells and other rapidly proliferating cells. This was proposed to
result from mTORC1 activation causing increased expression of HIF-1α (hypoxia-inducible
factor-1α), a transcription factor that increases expression of glycolytic enzymes [146].
Another study involved crossing mice with knockouts of the genes encoding p53
(Trp53) and AMPK-β1 (Prkab1), the major β subunit isoform expressed in T-cell precursors
in the thymus. Knockout of Prkab1 caused earlier onset of lymphomas in both homozygous
and heterozygous p53 knockouts, suggesting that β1 had a tumour suppressor role [147].
However, in both this model and the previous one, the knockouts of AMPK genes (Prkaa1 or
Prkab1) were global rather than T-cell specific, so it was not possible to conclude that these
were cell-intrinsic effects on AMPK in the tumour progenitor cells themselves. Another
mouse model used prostate -specific knockouts of both the tumour-suppressor gene Pten
and Prkab1; although the additional knockout of AMPK-β1 did not affect prostate size, it did
result in a higher proliferative index and pathological grade of tumour [148]. A drawback
with this model was that the prostate gland also expresses AMPK-β2, which might have
partially compensated for lack of β1 and might explain why the effects on tumourigenesis
were relatively modest.
These various limitations were recently overcome in a mouse model of T cell acute
lymphoblastic leukaemia/lymphoma (T-ALL), in which one or both of PTEN and AMPK-
α1 were knocked out in a conditional manner in T-cells which (as already mentioned) do
not express AMPK-α2 [149]. Knockout of Prkaa1 alone did not cause the appearance of any
lymphomas, but it accelerated the development of lymphomas induced by loss of the Pten
gene. As in the model of B-cell lymphoma discussed above [146], this was associated with
hyperactivation of mTORC1, and increased expression of HIF-1α and glycolytic enzymes,
over and above that observed upon knockout of Pten only. These results show that the
presence of AMPK-α1 protects, in a cell-intrinsic manner, against the development of
T-ALL triggered by PTEN loss.
A further question was addressed in this study: since the presence of AMPK-α1 in the
tumour progenitor cells provided protection against T-ALL, would additional protection
be provided by treatment with pharmacological activators of AMPK? These experiments
were inspired in part by earlier findings that the use of metformin to treat Type 2 diabetes,
compared with alternative treatments, is associated with a lower incidence of cancer
in humans [150]. Although this association has been observed across many diabetic
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cohorts [151], it remained unclear whether: (i) it was mediated by AMPK activation by
metformin; and (ii) it was a cell-intrinsic effect in the tumour progenitor cells themselves (for
example, it might have been due to the ability of metformin to lower plasma glucose and/or
insulin levels due to effects in other tissues or organs, such as the liver). The mouse model
of T-ALL [149] provided an excellent opportunity to answer these questions. Somewhat
disappointingly, oral treatment with metformin had no effect on the time of onset or the rate
of appearance of T-ALL induced by PTEN loss, irrespective of the presence or absence of
AMPK [149]. However, this could be ascribed to the demonstrated inability of the drug to
enter developing T-cells in the thymus, most likely due to a lack of expression of members
of the organic cation transporter family such as OCT1, which are required for metformin
uptake [149]. It was already known that the more hydrophobic biguanide drug phenformin
could readily enter cells lacking organic cation transporters [114], so phenformin was also
tested. Intriguingly, phenformin treatment significantly delayed the time of onset and the
rate of appearance of T-ALL induced by PTEN loss, but only when AMPK-α1 was present
in the tumour progenitor cells. This demonstrated not only that the tumour suppressor
effect of phenformin was AMPK-mediated but also, since all cells other than T-cells in
this conditional knockout model would have been expressing normal levels of AMPK-α1,
that this was a result of cell-intrinsic activation of AMPK in the tumour progenitor cells
themselves. Notably, of the mice that expressed AMPK in T-cells treated with phenformin,
four out of 14 had not developed any lymphomas by the termination of the experiment at
250 days of age, compared with only one out of 35 in the untreated group. Interestingly,
similar results had been previously obtained with mice that were heterozygous for PTEN
in a whole-body context, in which oral treatment with metformin, phenformin or A-769662
significantly delayed tumour formation in various organs or tissues [152]. Although these
results show that AMPK-activating drugs can protect against the development of cancer, it
is worth noting that in both cases the treatment was started before any tumours had become
evident. If these findings do have any relevance to medical practice in humans, it might
therefore be that AMPK activators could be used to prevent or delay cancer in individuals
who were at high risk of its development because of other genetic factors, analogous to the
mice with the T-cell-specific knockout of PTEN (Figure 9). Another point to note here is
that phenformin was withdrawn for the treatment of Type 2 diabetes in 1978 because its
use was associated with cases of lactic acidosis. This side-effect occurs with metformin as
well as phenformin, although it is much less common with the former (≈three cases per
100,000 patient-years, as opposed to >60 with phenformin [153]). Nevertheless, even with
phenformin, this complication (while life-threatening) is rare, and the risk may be more
acceptable during prevention of cancer than for long-term treatment of diabetes.
Other evidence supporting the idea that AMPK is a tumour suppressor comes from
studies of oncoproteins that are ubiquitin ligases and that appear to be involved in the cellu-
lar degradation of AMPK. For example, MAGE-A3/-A6 are two closely related members of
the melanoma antigen family, which are normally only expressed in testis but become aber-
rantly re-expressed in some tumours (hence their designation as tumour antigens) [154].
They bind to the ubiquitin E3 ligase TRIM28, and a screen revealed AMPK-α1 to be a target
for polyubiquitylation by this complex, resulting in its proteasomal degradation. Support-
ing this, knockdown of MAGE-A3/A6 or TRIM28 in tumour cells increased the expression
of AMPK-α1 and triggered changes in metabolism and signalling that would be expected
downstream of AMPK, including inhibition of mTORC1. Moreover, various human tumour
cells that express MAGE-A3/-A6 have reduced levels of AMPK-α1 protein [154]. Another
example is provided by the cancer-associated ubiquitin ligase, UBE2O [155]. As expected
for an oncogene, knockout of the Ube2o gene in mice was found to attenuate tumourigenesis
in models of both breast and prostate cancer. Interestingly, AMPK-α2 was identified as a
UBE2O-interacting protein that is targeted for polyubiquitylation and consequent protea-
somal degradation by the ubiquitin ligase. Consistent with this, expression of AMPK-α2
(but not -α1) was upregulated in Ube2o knockout mice. A human colon cancer cell line also
grew less rapidly in mouse xenografts when UBE2O was knocked down using shRNA,
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and this was reversed by the simultaneous knockdown of AMPK-α2, but not -α1. Finally,
the UBE2O gene in humans is located at a region of chromosome 17 that is amplified in
many cancers. Using immunohistochemistry, there was a negative correlation between
expression of UBE2O and AMPK-α2, but a positive correlation with S6 phosphorylation,
indicating up-regulation of the mTORC1 pathway, in human breast cancers. Taken together,
these results suggest that either AMPK-α1 or AMPK-α2 can act as tumour suppressors in
human cancer, depending upon the cellular context.
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Figure 9. The central dichotomy in the functions of AMPK as a target in cancer therapy. LEFT:
by inhibiting biosynthesis and thus cell growth, the cell cycle and thus cell proliferation, and mTORC1
and thus metabolic changes conducive to cell growth, AMPK activators such as phenformin can
prevent or delay cancer initiation. RIGHT: once cancer has arisen, AMPK may switch to promoting
survival of cancer cells, by protecting them against the hypoxic, nutrient/energy and DNA replication
stresses to which they might otherwise become vulnerable.
5.2. Evidence from Mouse Models That AMPK Is a Tumour Promoter
As discussed in the previous section, some of the strongest evidence in favour of
AMPK being a cell-intrinsic tumour suppressor came from a study of a mouse model
of T-ALL [149]. Surprisingly, studies of the same cancer type using a different murine
model came up with the opposite conclusion [156]. In the latter study, T-ALL tumour
cells were generated in vitro by retroviral expression of an oncogenic NOTCH1 mutant in
mouse haematopoietic stem cells that also carried a floxed Prkaa1 (AMPK-α1) gene and a
Cre recombinase gene driven by a tamoxifen-inducible promoter. The transformed cells
were multiplied in irradiated mice and then injected into secondary irradiated recipient
mice. After allowing the disease to become established for 10 days, these mice were then
treated with tamoxifen to acutely delete AMPK-α1 in the T-ALL cells in vivo. In this model,
knocking out AMPK reduced the recovery of T-ALL cells in spleen, lymph nodes and
bone marrow, and enhanced survival of the mice [156]. Thus, the presence of AMPK-α1
was promoting the proliferation of T-ALL cells and making the disease more aggressive,
suggesting that AMPK-α1 was acting as a tumour promoter. How can this be reconciled
with the study described in Section 5.1, where AMPK-α1 appeared to be acting as a
tumour suppressor in a different mouse model of T-ALL? The key difference between
these studies is that, in the latter [149], AMPK had been knocked out, or treatment with
AMPK-activating drugs initiated, prior to the development of disease, whereas in the other
study [156], AMPK was present while the disease was developing and was only knocked
out after it had become established. By inhibiting cell growth and proliferation, and by
opposing the activation of pathways that promote those processes such as the mTORC1
pathway, it seems reasonable that AMPK would oppose the initiation of tumours, thus
acting as a tumour suppressor. However, if (despite the best efforts of AMPK) tumours
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nevertheless did become established due to activating mutations in proto-oncogenes or
loss-of-function mutations in other tumour suppressors, then AMPK may simply switch
to become a tumour promoter instead (Figure 9). Note that the AMPK system most
likely evolved as a stress response system that protected single-celled eukaryotes against
energetic or nutritional stress. This ancestral, cell-intrinsic function remains relevant in
cells of multicellular organisms today, irrespective of whether they are normal cells or
tumour cells. Because their rapid growth often outstrips the ability of their blood supply to
provide adequate nutrients and oxygen, tumour cells (and solid tumours in particular) will
often be under energetic or nutritional stress. Paradoxically, by slowing cell growth and
proliferation once it is activated by the stress, and by adjusting metabolism to respond to
the stressful situation, the presence of AMPK may aid survival of the tumour cells and thus
in the long term have a tumour-promoting effect, which would be good for the cancer cells
but bad for the patient. We therefore propose that, while activators of AMPK may prove to
be useful in prevention of cancer, most likely in individuals who have a high genetic risk
of developing the disease, inhibitors of AMPK may instead be efficacious in the treatment
of pre-existing cancers.
Another study suggesting that AMPK can promote tumour growth involved a mouse
model of non-small cell lung cancer in which the tumours develop in situ at their site of
origin, and in which both AMPK-α1 and -α2 were knocked out [157]. Mice harbouring
Lox-STOP-Lox alleles of the KrasG12D oncogene and firefly luciferase were crossed with
mice expressing floxed alleles of the genes encoding p53, LKB1, and AMPK-α1 plus -α2.
Cre-recombinase was delivered to the lungs by nasal inhalation of lentiviral vectors, trig-
gering recombination at twin loxP sites in a small subset of lung epithelial cells, so that
expression of the KrasG12D oncogene and luciferase would be switched on, while different
combinations of p53, LKB1, and AMPK-α1 plus -α2 would be simultaneously knocked out;
growth of tumours could be monitored in vivo via bioluminescence from the expressed
luciferase. Knockout of LKB1 enhanced growth of tumours expressing mutant K-Ras as
reported previously [158] but, by contrast, knockout of both AMPK-α1 and -α2 was found
to cause reductions in the size and number of lung tumours in KrasG12D Trp53−/− mice.
Overall, these results confirmed that LKB1 is a tumour suppressor in non-small cell lung
cancer, while the presence of both AMPK-α1 or -α2 promoted tumour growth [157].
5.3. Evidence from Genetic Changes in AMPK Genes in Human Cancer
Although the most definitive evidence for the contrasting roles of AMPK in cancer
has come from the study of mouse models, analysis of genetic changes that are associ-
ated with human cancers can provide revealing clues and circumstantial evidence. The
cBioPortal database [159,160] provides a user-friendly platform to interrogate genetic
changes occurring in human cancers for any particular gene, based on the numerous
genomic studies of different cancer types that have been performed. Recent analyses of
this database [1,140,161] revealed that, while the PRKAA2 gene encoding AMPK-α2 is
often mutated in human cancers, the PRKAA1 gene encoding AMPK-α1 (also, interestingly,
the PRKAB2 gene encoding AMPK-β2) is often amplified instead. While not providing
conclusive proof, these results suggest that, if anything, AMPK-α2 may act as a tumour
suppressor in human cancers, while AMPK-α1 (and -β2) are more likely to represent
tumour-promoting genes. In fact, some evidence for a similar isoform selectivity was
obtained with studies of transformed mouse embryo fibroblasts (MEFs) performed several
years ago [162]. Primary MEFs from wild type (WT), AMPK-α1 or AMPK-α2 knockout
(KO) mice were transformed by expression of V12 mutant H-Ras in vitro; the α1-KO cells
grew at a slow rate similar to that of the WT, while the α2-KO cells grew significantly more
rapidly that the WT cells and, unlike the latter, also formed colonies in soft agar. Consistent
with this, when grown as solid tumours in the flanks of nude mice, only the α2-KO cells
grew rapidly; the WT cells grew much more slowly after a longer lag phase, while the
α1-KO cells did not grow at all [162]. These findings are consistent with the view that,
while AMPK-α2 is a tumour suppressor in that tumour growth is accelerated when it is
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lost, AMPK-α1 is a tumour promoter whose presence is required for the growth of cancer
cells in vivo.
For reasons that remain unclear, mutations in the PRKAA2 gene are particularly
frequent in human skin cancer and melanoma, where, in several different studies, they
occurred in 10–23% of cases, while amplification of PRKAA1 is common in adenocarcinoma
and squamous cell carcinoma of the lung, where it has been found to occur in 8–11% of
cases [140]. Although the proportion of the cancer mutations in PRKAA2 that cause loss-of-
function is not yet clear, the occurrence of frequent mutations suggests that, if anything,
AMPK-α2 is acting as a tumour suppressor. By contrast, the fact that the genes encoding
AMPK-α1 and -β2 are frequently amplified suggests that these are tumour promoters where
gene amplification is being selected for because it aids tumour cell growth. One caveat with
this is that gene amplifications in cancer do not usually just affect single genes, but instead
whole segments of chromosomes containing multiple genes. It therefore remains possible
that PRKAA1 (and/or PRKAB2) are located in the genome near to another oncogene whose
amplification is being selected for in the tumour cells, with the AMPK genes merely being
innocent passengers. Arguing against this in the case of PRKAA1, however, is analysis of
simultaneous genetic changes in known oncogenes and tumour suppressors that occur
within the same cases of cancer. For example, in 230 cases of lung adenocarcinoma studied
by The Cancer Genome Atlas (TCGA) network [163], the PRKAA1 gene was amplified
in 22 (10%), while the STK11 gene (encoding the upstream kinase LKB1) was subject to
either deletions, or mutations expected to cause loss-of-function, in 43 (19%). However,
these changes never occurred together in the same case. The probability (p) that this would
occur by random chance if the two genes were behaving independently was <0.005 [1].
These results suggest that the increased activity of AMPK-α1 due to gene amplification had
been the subject of positive selection, because if the kinase activity of AMPK was irrelevant
to the function of the cancer cells, there would have been no necessity to maintain LKB1
function.
Two other genes subject to particularly frequent mutations in lung adenocarcinomas
are KRAS, encoding the K-Ras variant of the small G protein Ras (36% of cases), and TP53,
encoding the tumour suppressor and transcription factor p53 (47% of cases). Interestingly,
in the TCGA study [163] there was a significant mutual exclusion between amplification of
PRKAA1 and mutations in KRAS (p < 0.005), but a significant co-occurrence with mutations
in TP53 (p < 0.001) [1]. In the 22 cases of lung adenocarcinoma with amplification of
PRKAA1, only 3 were not also associated with loss-of-function mutations in TP53 [140].
Thus, amplification of AMPK-α1 (and normal function of LKB1) seems to be selected for in
tumours driven by the loss of p53 function—why should this be? The classical role of p53 is
to become stabilized or activated in response to DNA damage, and to cause a G1 cell cycle
arrest, which it achieves by inducing transcription of genes such as CDKN1A encoding the
G1 cyclin-dependent kinase inhibitor p21CIP1. This allows time either for the DNA damage
to be repaired, or for further proliferation of the aberrant cell to be prevented by induction
of senescence or apoptosis [164]. AMPK, and specifically the α1 isoform that is amplified in
some cancers, is selectively activated in the cell nucleus by genotoxic treatments, providing
protection against cell death induced by such treatments, at least in part by up-regulating
expression of p21CIP1 [7]. Thus, amplification of the PRKAA1 gene may be being selected
for in TP53-mutant tumours because it can compensate for the lack of p53 and protect the
tumour cells against genotoxic stresses that might otherwise kill them. If this hypothesis is
correct, then AMPK inhibitors, especially if α1-selective, might be a particularly effective
adjunct to cytotoxic treatments of p53-mutant tumours.
5.4. Role of AMPK in Cancer Stem Cells
Recently, interest has been growing in the role of cancer stem cells (CSCs) in the
initiation, progression, resistance to drug therapy and recurrence of tumours. AMPK
has been suggested either to hinder or promote the development of CSCs, although the
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evidence for the latter view is more limited. Moreover, AMPK activation has been reported
to restore the sensitivity of cancer cells to chemotherapeutics.
A significant body of evidence exists suggesting a role for metformin, a known
activator of AMPK (Section 4.2), in reduced survival or inhibition of growth of cancer stem
cells, as well as inhibition of their differentiation potential and expression of stemness
markers [165–171]. Many of these studies used metformin at concentrations of 1–10 mM
or even higher, which is well above the peak plasma concentrations of metformin when
given at normal doses in humans. However, Struhl’s laboratory [171] reported effects of
metformin on CSCs derived from breast cancers at the more pharmacologically relevant
concentration of 100 µM. Interestingly, at this dose metformin synergized with a variety
of chemotherapeutics in a range of cancer cell lines to block tumour growth and prevent
relapse [172]. Metformin at 30–100 µM also induced radiosensitization of pancreatic cancer
cells in an AMPK-dependent manner [173]. In addition, both metformin and A-769662
(the latter a direct activator of AMPK that acts in a manner different from metformin by
binding at the ADaM site, Section 4.3), were reported to impede the generation of induced
pluripotent stem cells (iPSC) from fibroblasts [174].
It is now clear that metformin has some metabolic effects that are not mediated by
AMPK (e.g., [91,92]), so it was important to demonstrate that the effects of metformin on
CSCs were dependent upon AMPK. Supporting this, AMPK knockdown using siRNA
reduced the differentiation-promoting effects of metformin on stem-like glioma-initiating
cells [175]. In another study [176], a CSC-like phenotype was induced in hepatocellular
carcinoma cells by selecting for a cell population resistant to the ant-cancer drug sorafenib;
the resulting cells had impaired AMPK signalling and increased expression of stem cell
markers. However, both stemness and the induced drug resistance could be reduced or
reversed either by exogenous expression of AMPK, or by its activation using A-769662.
Conversely, knockdown of AMPK using siRNA in the original cell lines was sufficient to
induce expression of stemness markers and resistance to drug treatment [176].
A number of mechanisms have been suggested to explain regulation of stemness
by AMPK, primarily related to the modulation of expression of pluripotency-related
transcription factors. Thus, AMPK inhibits activation of STAT3, a transcription factor that
activates expression of the iPSC markers NANOG, OCT4 and SOX2 [177]. AMPK was
also reported to induce the degradation of NANOG by inhibiting its BRAF-dependent
phosphorylation, resulting in increased interaction with an E3 ubiquitin ligase adaptor
protein, SPOP, and subsequent ubiquitin-mediated degradation [178].
If AMPK does indeed suppress CSCs, we find ourselves in the paradoxical situation
where inhibition of AMPK might inhibit the growth of the bulk of the tumour, while
potentially also taking the brakes off the proliferation of tumour-initiating cancer stem cells.
In such a situation, AMPK activators (rather than inhibitors) might be useful to prevent
metastasis after chemotherapy or surgery. However, as always with AMPK, the cellular
context appears to be critical. In contrast to the studies cited above, Saito et al. [179] have
demonstrated that, under conditions of severe metabolic stress (a combination of dietary
restriction and the hypoxic environment of the bone marrow), AMPK deletion significantly
reduced the population of leukaemia-initiating cells in the bone marrow, but not in the
relatively more benign environment of the spleen [179].
6. Conclusions
Our understanding of the role of AMPK in cancer is continually evolving, which is
perhaps not surprising given the complex, multifaceted functions of this kinase and the
heterogeneous nature of the disease. Much has been done in the last few years to begin to
refine our models of the actions of AMPK in cancer, and exciting times undoubtedly lie
ahead. We await with great interest studies examining the potential of AMPK inhibitors
to treat established cancers, although the lack of truly specific inhibitors is a current
impediment—we therefore also hope to see much more selective inhibitors emerging from
the drug development pipelines.
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The disparity in the function of AMPK in different cancer models suggests that it might
well be a target for the developing field of personalised medicine. Clearly, AMPK inhibitors
would be expected to be particularly effective in metabolically compromised tumours
that have amplification of the PRKAA1 gene, as is seen in a significant proportion of lung
cancers. Given the high incidence of mutations of AMPK-α2 in cancer, especially in skin
cancer and melanoma, the ideal inhibitor would also be selective, if not completely specific,
for the α1 isoform. However, even non-isoform-selective AMPK inhibitors, by rendering
cells more sensitive to DNA damage, may have potential to be effective adjuncts when
administered with conventional cytotoxic treatments.
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Abbreviations
ACC Acetyl-CoA carboxylase
ADaM Allosteric drug and metabolite (binding site on AMPK heterotrimer)
AICA 5-aminoimidazole-4-carboxamide
α-AID Autoinhibitory domain of the AMPK-α subunit
AMPK AMP-activated protein kinase
ARK AMPK-related kinase
ASA Acetyl salicylic acid
ATIC Human gene encoding both AICAR transformylase and IMP cyclohydrolase
ATM Serine-protein kinase ATM (Ataxia telangiectasia mutated)
CaMKI Calmodulin-dependent kinase-I
CaMKK2 Ca2+/calmodulin-dependent kinase kinase-2 (-β)
β-CBM Carbohydrate-binding module of the AMPK-β subunit
CBS Cystathionine β-synthase (refers to CBS domain or CBS repeat)
CBS1 CBS repeat 1; refers to an adenine nucleotide-binding site on the AMPK-γ subunit
CBS3 CBS repeat 3; refers to an adenine nucleotide-binding site on the AMPK-γ subunit
CBS4 CBS repeat 4; refers to an adenine nucleotide-binding site on the AMPK-γ subunit
C-lobe C-terminal lobe of a kinase domain
CSCs Cancer stem cells
α-CTD C-terminal domain of the AMPK-α subunit
β-CTD C-terminal domain of the AMPK-β subunit
EXO1 Exonuclease 1
FBP Fructose-1,6-bisphosphate
GHSR1 Growth hormone secretagogue receptor-1
IGF-1 Insulin-like growth factor-1
IP3 Inositol-1,4,5-triphosphate
iPSCs Inducible pluripotent stem cells
α-KD Kinase domain of the AMPK-α subunit
KO Knockout
LCFA Long chain fatty acid
α-linker Linker region of the AMPK-α subunit
LKB1 Liver kinase B-1
MAGE Melanoma antigen gene (a gene family)
MEFs Mouse embryonic fibroblasts
MO25 Mouse protein 25
mTORC1 mammalian (or mechanistic) target-of-rapamycin complex-1
NES Nuclear exclusion sequence
N-lobe N-terminal lobe of a kinase domain
NLS Nuclear localization sequence
NOTCH1 Neurogenic locus notch homolog protein 1
OCT1 Organic cation transporter 1
PPP1R3C Human gene encoding a glycogen-targetting regulatory subunit of proteinphosphatase-1
PRKAA1 Human gene encoding AMPK-α1
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PRKAA2 Human gene encoding AMPK-α2
PRKAB1 Human gene encoding AMPK-β1
PRKAG1 Human gene encoding AMPK-γ1
PRKAG2 Human gene encoding AMPK-γ2
PRKAG3 Human gene encoding AMPK-γ3
PTEN Phosphatase and tensin homolog protein
shRNA Short hairpin RNA
siRNA Small interfering RNA
STRAD Ste20-related adaptor
STK11 Human gene encoding LKB1
ST loop Serine/threonine-rich regulatory loop near the C-terminus of the AMPK-α subunit
T-ALL T cell acute lymphoblastic leukameia/lymphoma
TCGA The Cancer Genome Atlas
TRIM-28 Tripartite motif containing 28 (ubiquitin E3 ligase)
UBE2O E2/E3 hybrid ubiquitin-protein ligase
VEGF Vascular endothelial cell growth factor
ZMP 5-aminoimidazole-4-carboxamide ribonucleoside monophosphate
References
1. Vara-Ciruelos, D.; Russell, F.M.; Hardie, D.G. The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde? Open Biol. 2019, 9,
190099. [CrossRef]
2. Hardie, D.G. Keeping the home fires burning: AMP-activated protein kinase. J. R. Soc. Interface 2018, 15, 20170774. [CrossRef]
3. Lin, S.C.; Hardie, D.G. AMPK: Sensing glucose as well as cellular energy status. Cell Metab. 2017, 27, 299–313. [CrossRef]
4. Hardie, D.G.; Hawley, S.A. AMP-activated protein kinase: The energy charge hypothesis revisited. BioEssays 2001, 23, 1112–1119.
[CrossRef]
5. Gonzalez, A.; Hall, M.N.; Lin, S.C.; Hardie, D.G. AMPK and TOR: The Yin and Yang of cellular nutrient sensing and growth
control. Cell Metab. 2020, 31, 472–492. [CrossRef]
6. Zhang, C.S.; Hawley, S.A.; Zong, Y.; Li, M.; Wang, Z.; Gray, A.; Ma, T.; Cui, J.; Feng, J.W.; Zhu, M.; et al. Fructose-1,6-bisphosphate
and aldolase mediate glucose sensing by AMPK. Nature 2017, 548, 112–116. [CrossRef]
7. Vara-Ciruelos, D.; Dandapani, M.; Gray, A.; Egbani, E.O.; Evans, A.M.; Hardie, D.G. Genotoxic damage activates the AMPK-
alpha1 isoform in the nucleus via Ca2+/CaMKK2 signaling to enhance tumor cell survival. Mol. Cancer Res. 2018, 16, 345–357.
[CrossRef]
8. Li, S.; Lavagnino, Z.; Lemacon, D.; Kong, L.; Ustione, A.; Ng, X.; Zhang, Y.; Wang, Y.; Zheng, B.; Piwnica-Worms, H.; et al.
Ca(2+)-stimulated AMPK-dependent phosphorylation of Exo1 protects stressed replication forks from aberrant resection. Mol.
Cell 2019, 74, 1123–1137. [CrossRef]
9. Hardie, D.G.; Schaffer, B.E.; Brunet, A. AMPK: An energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol.
2016, 26, 190–201. [CrossRef]
10. Zong, Y.; Zhang, C.S.; Li, M.; Wang, W.; Wang, Z.; Hawley, S.A.; Ma, T.; Feng, J.W.; Tian, X.; Qi, Q.; et al. Hierarchical activation of
compartmentalized pools of AMPK depends on severity of nutrient or energy stress. Cell Res. 2019, 29, 460–473. [CrossRef]
11. Munday, M.R.; Campbell, D.G.; Carling, D.; Hardie, D.G. Identification by amino acid sequencing of three major regulatory
phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 1988, 175, 331–338. [CrossRef] [PubMed]
12. Myers, R.W.; Guan, H.P.; Ehrhart, J.; Petrov, A.; Prahalada, S.; Tozzo, E.; Yang, X.; Kurtz, M.M.; Trujillo, M.; Trotter, D.G.; et al.
Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 2017, 357,
507–511. [CrossRef] [PubMed]
13. Hawley, S.A.; Davison, M.; Woods, A.; Davies, S.P.; Beri, R.K.; Carling, D.; Hardie, D.G. Characterization of the AMP-activated
protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated
protein kinase. J. Biol. Chem. 1996, 271, 27879–27887. [CrossRef] [PubMed]
14. Ross, F.A.; Jensen, T.E.; Hardie, D.G. Differential regulation by AMP and ADP of AMPK complexes containing different gamma
subunit isoforms. Biochem. J. 2016, 473, 189–199. [CrossRef]
15. Xiao, B.; Sanders, M.J.; Underwood, E.; Heath, R.; Mayer, F.V.; Carmena, D.; Jing, C.; Walker, P.A.; Eccleston, J.F.; Haire, L.F.; et al.
Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472, 230–233. [CrossRef]
16. Oakhill, J.S.; Steel, R.; Chen, Z.P.; Scott, J.W.; Ling, N.; Tam, S.; Kemp, B.E. AMPK is a direct adenylate charge-regulated protein
kinase. Science 2011, 332, 1433–1435. [CrossRef]
17. Oakhill, J.S.; Chen, Z.P.; Scott, J.W.; Steel, R.; Castelli, L.A.; Ling, N.; Macaulay, S.L.; Kemp, B.E. β-Subunit myristoylation is the
gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad. Sci. USA 2010, 107,
19237–19241. [CrossRef]
18. Hawley, S.A.; Boudeau, J.; Reid, J.L.; Mustard, K.J.; Udd, L.; Makela, T.P.; Alessi, D.R.; Hardie, D.G. Complexes between the LKB1
tumor suppressor, STRADa/b and MO25a/b are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2,
28. [CrossRef]
19. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.;
Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13, 2004–2008. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 186 24 of 30
20. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1
kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA
2004, 101, 3329–3335. [CrossRef]
21. Zeqiraj, E.; Filippi, B.M.; Deak, M.; Alessi, D.R.; van Aalten, D.M. Structure of the LKB1-STRAD-MO25 complex reveals an
allosteric mechanism of kinase activation. Science 2009, 326, 1707–1711. [CrossRef] [PubMed]
22. Alessi, D.R.; Sakamoto, K.; Bayascas, J.R. Lkb1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75, 137–163. [CrossRef]
[PubMed]
23. Wingo, S.N.; Gallardo, T.D.; Akbay, E.A.; Liang, M.C.; Contreras, C.M.; Boren, T.; Shimamura, T.; Miller, D.S.; Sharpless, N.E.;
Bardeesy, N.; et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 2009, 4, e5137. [CrossRef] [PubMed]
24. Davies, S.P.; Helps, N.R.; Cohen, P.T.; Hardie, D.G. 5’-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of
the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine
protein phosphatase-2AC. FEBS Lett. 1995, 377, 421–425. [PubMed]
25. Wang, L.; Brautigan, D.L. alpha-SNAP inhibits AMPK signaling to reduce mitochondrial biogenesis and dephosphorylates
Thr172 in AMPKalpha in vitro. Nature Commun. 2013, 4, 1559. [CrossRef]
26. Yin, D.; Huang, P.; Wu, J.; Song, H. Drosophila protein phosphatase V regulates lipid homeostasis via the AMPK pathway. J. Mol.
Cell. Biol. 2014, 6, 100–102. [CrossRef]
27. Taylor, S.S.; Kornev, A.P. Protein kinases: Evolution of dynamic regulatory proteins. Trends Biochem. Sci. 2011, 36, 65–77.
[CrossRef]
28. Chen, L.; Jiao, Z.H.; Zheng, L.S.; Zhang, Y.Y.; Xie, S.T.; Wang, Z.X.; Wu, J.W. Structural insight into the autoinhibition mechanism
of AMP-activated protein kinase. Nature 2009, 459, 1146–1149. [CrossRef]
29. Li, X.; Wang, L.; Zhou, X.E.; Ke, J.; de Waal, P.W.; Gu, X.; Tan, M.H.; Wang, D.; Wu, D.; Xu, H.E.; et al. Structural basis of AMPK
regulation by adenine nucleotides and glycogen. Cell Res. 2015, 25, 50–66. [CrossRef]
30. Xiao, B.; Sanders, M.J.; Carmena, D.; Bright, N.J.; Haire, L.F.; Underwood, E.; Patel, B.R.; Heath, R.B.; Walker, P.A.; Hallen, S.; et al.
Structural basis of AMPK regulation by small molecule activators. Nature Commun. 2013, 4, 3017. [CrossRef]
31. Horman, S.; Vertommen, D.; Heath, R.; Neumann, D.; Mouton, V.; Woods, A.; Schlattner, U.; Wallimann, T.; Carling, D.; Hue, L.;
et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via
hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 2006, 281, 5335–5340. [CrossRef] [PubMed]
32. Hurley, R.L.; Barre, L.K.; Wood, S.D.; Anderson, K.A.; Kemp, B.E.; Means, A.R.; Witters, L.A. Regulation of AMP-activated
protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J. Biol. Chem. 2006, 281, 36662–36672.
[CrossRef] [PubMed]
33. Heathcote, H.R.; Mancini, S.J.; Strembitska, A.; Jamal, K.; Reihill, J.A.; Palmer, T.M.; Gould, G.W.; Salt, I.P. Protein kinase C
phosphorylates AMP-activated protein kinase alpha1 Ser487. Biochem. J. 2016, 473, 4681–4697. [CrossRef] [PubMed]
34. Suzuki, T.; Bridges, D.; Nakada, D.; Skiniotis, G.; Morrison, S.J.; Lin, J.D.; Saltiel, A.R.; Inoki, K. Inhibition of AMPK catabolic
action by GSK3. Mol. Cell 2013, 50, 407–419. [CrossRef] [PubMed]
35. Hawley, S.A.; Ross, F.A.; Gowans, G.J.; Tibarewal, P.; Leslie, N.R.; Hardie, D.G. Phosphorylation by Akt within the ST loop of
AMPK-α1 down-regulates its activation in tumour cells. Biochem. J. 2014, 459, 275–287. [CrossRef]
36. Kazgan, N.; Williams, T.; Forsberg, L.J.; Brenman, J.E. Identification of a nuclear export signal in the catalytic subunit of
AMP-activated protein kinase. Mol. Biol. Cell 2010, 21, 3433–3442. [CrossRef]
37. Salt, I.P.; Celler, J.W.; Hawley, S.A.; Prescott, A.; Woods, A.; Carling, D.; Hardie, D.G. AMP-activated protein kinase—Greater
AMP dependence, and preferential nuclear localization, of complexes containing the a2 isoform. Biochem. J. 1998, 334, 177–187.
[CrossRef]
38. Turnley, A.M.; Stapleton, D.; Mann, R.J.; Witters, L.A.; Kemp, B.E.; Bartlett, P.F. Cellular distribution and developmental expression
of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 1999, 72, 1707–1716. [CrossRef]
39. McGee, S.L.; Howlett, K.F.; Starkie, R.L.; Cameron-Smith, D.; Kemp, B.E.; Hargreaves, M. Exercise increases nuclear AMPK
alpha-2 in human skeletal muscle. Diabetes 2003, 52, 926–928. [CrossRef]
40. Ai, H.; Ihlemann, J.; Hellsten, Y.; Lauritzen, H.P.; Hardie, D.G.; Galbo, H.; Ploug, T. Effect of fiber type and nutritional state on
AICAR- and contraction-stimulated glucose transport in rat muscle. Am. J. Physiol. 2002, 282, E1291–E1300. [CrossRef]
41. Suzuki, A.; Okamoto, S.; Lee, S.; Saito, K.; Shiuchi, T.; Minokoshi, Y. Leptin stimulates fatty acid oxidation and peroxisome
proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the
alpha2 form of AMP-activated protein kinase. Mol. Cell. Biol. 2007, 27, 4317–4327. [CrossRef] [PubMed]
42. Warden, S.M.; Richardson, C.; O’Donnell, J., Jr.; Stapleton, D.; Kemp, B.E.; Witters, L.A. Post-translational modifications of the
beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem. J. 2001, 354 Pt 2, 275–283.
[CrossRef]
43. McLaughlin, S.; Aderem, A. The myristoyl-electrostatic switch: A modulator of reversible protein-membrane interactions. Trends
Biochem. Sci. 1995, 20, 272–276. [CrossRef]
44. Machovic, M.; Janecek, S.H. The evolution of putative starch-binding domains. FEBS Lett. 2006, 580, 6349–6356. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2021, 22, 186 25 of 30
45. Hudson, E.R.; Pan, D.A.; James, J.; Lucocq, J.M.; Hawley, S.A.; Green, K.A.; Baba, O.; Terashima, T.; Hardie, D.G. A novel domain
in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr.
Biol. 2003, 13, 861–866. [CrossRef]
46. Polekhina, G.; Gupta, A.; Michell, B.J.; van Denderen, B.; Murthy, S.; Feil, S.C.; Jennings, I.G.; Campbell, D.J.; Witters, L.A.;
Parker, M.W.; et al. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. 2003, 13, 867–871. [CrossRef]
47. Polekhina, G.; Gupta, A.; van Denderen, B.J.; Feil, S.C.; Kemp, B.E.; Stapleton, D.; Parker, M.W. Structural basis for glycogen
recognition by AMP-activated protein kinase. Structure 2005, 13, 1453–1462. [CrossRef]
48. Jorgensen, S.B.; Nielsen, J.N.; Birk, J.B.; Olsen, G.S.; Viollet, B.; Andreelli, F.; Schjerling, P.; Vaulont, S.; Hardie, D.G.; Hansen, B.F.;
et al. The a2-5′AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose
loading. Diabetes 2004, 53, 3074–3081. [CrossRef]
49. Bultot, L.; Guigas, B.; Von Wilamowitz-Moellendorff, A.; Maisin, L.; Vertommen, D.; Hussain, N.; Beullens, M.; Guinovart, J.J.;
Foretz, M.; Viollet, B.; et al. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. Biochem. J.
2012, 443, 193–203. [CrossRef]
50. Vernia, S.; Solaz-Fuster, M.C.; Gimeno-Alcaniz, J.V.; Rubio, T.; Garcia-Haro, L.; Foretz, M.; de Cordoba, S.R.; Sanz, P. AMP-activated
protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and
accelerates its down-regulation by the laforin-malin complex. J. Biol. Chem. 2009, 284, 8247–8255. [CrossRef]
51. Ducommun, S.; Deak, M.; Zeigerer, A.; Goransson, O.; Seitz, S.; Collodet, C.; Madsen, A.B.; Jensen, T.E.; Viollet, B.; Foretz, M.;
et al. Chemical genetic screen identifies Gapex-5/GAPVD1 and STBD1 as novel AMPK substrates. Cell. Signal. 2019, 57, 45–57.
[CrossRef] [PubMed]
52. Hoffman, N.J.; Whitfield, J.; Janzen, N.R.; Belhaj, M.R.; Galic, S.; Murray-Segal, L.; Smiles, W.J.; Ling, N.X.Y.; Dite, T.A.;
Scott, J.W.; et al. Genetic loss of AMPK-glycogen binding destabilizes AMPK and disrupts metabolism. Mol. Metab. 2020, 41,
101048. [CrossRef] [PubMed]
53. Bateman, A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci.
1997, 22, 12–13. [CrossRef]
54. Ignoul, S.; Eggermont, J. CBS domains: Structure, function, and pathology in human proteins. Am. J. Physiol. Cell Physiol. 2005,
289, C1369–C1378. [CrossRef] [PubMed]
55. Scott, J.W.; Hawley, S.A.; Green, K.A.; Anis, M.; Stewart, G.; Scullion, G.A.; Norman, D.G.; Hardie, D.G. CBS domains form
energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 2004, 113, 274–284.
[CrossRef] [PubMed]
56. Kemp, B.E.; Oakhill, J.S.; Scott, J.W. AMPK structure and regulation from three angles. Structure 2007, 15, 1161–1163. [CrossRef]
57. Gu, X.; Yan, Y.; Novick, S.J.; Kovich, A.; Goswami, D.; Ke, J.; Tan, M.H.E.; Wang, L.; Li, X.; de Waal, P.; et al. Deconvoluting
AMP-dependent kinase (AMPK) adenine nucleotide binding and sensing. J. Biol. Chem. 2017, 292, 12653–12666. [CrossRef]
58. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F.C.; Leone, P.; Jing, C.; Walker, P.A.; Haire, L.; Eccleston, J.F.; Davis, C.T.; et al. Structural basis
for AMP binding to mammalian AMP-activated protein kinase. Nature 2007, 449, 496–500. [CrossRef]
59. Salt, I.P.; Johnson, G.; Ashcroft, S.J.H.; Hardie, D.G. AMP-activated protein kinase is activated by low glucose in cell lines derived
from pancreatic b cells, and may regulate insulin release. Biochem. J. 1998, 335, 533–539. [CrossRef]
60. Li, M.; Zhang, C.S.; Zong, Y.; Feng, J.W.; Ma, T.; Hu, M.; Lin, Z.; Li, X.; Xie, C.; Wu, Y.; et al. Transient Receptor Potential V
channels are essential for glucose sensing by aldolase and AMPK. Cell Metab. 2019, 30, 508–524. [CrossRef]
61. Woods, A.; Munday, M.R.; Scott, J.; Yang, X.; Carlson, M.; Carling, D. Yeast SNF1 is functionally related to mammalian
AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo. J. Biol. Chem. 1994, 269, 19509–19515. [PubMed]
62. Wilson, W.A.; Hawley, S.A.; Hardie, D.G. Glucose repression/derepression in budding yeast: SNF1 protein kinase is activated by
phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Curr. Biol. 1996, 6, 1426–1434.
[CrossRef]
63. Baena-Gonzalez, E.; Rolland, F.; Thevelein, J.M.; Sheen, J. A central integrator of transcription networks in plant stress and energy
signalling. Nature 2007, 448, 938–942. [CrossRef] [PubMed]
64. Thelander, M.; Olsson, T.; Ronne, H. Snf1-related protein kinase 1 is needed for growth in a normal day-night light cycle. EMBO J.
2004, 23, 1900–1910. [CrossRef] [PubMed]
65. Mackintosh, R.W.; Davies, S.P.; Clarke, P.R.; Weekes, J.; Gillespie, J.G.; Gibb, B.J.; Hardie, D.G. Evidence for a protein kinase
cascade in higher plants. 3-Hydroxy-3-methylglutaryl-CoA reductase kinase. Eur. J. Biochem. 1992, 209, 923–931. [CrossRef]
[PubMed]
66. Mayer, F.V.; Heath, R.; Underwood, E.; Sanders, M.J.; Carmena, D.; McCartney, R.R.; Leiper, F.C.; Xiao, B.; Jing, C.;
Walker, P.A.; et al. ADP regulates SNF1, the Saccharomyces cerevisiae homolog of AMP-activated protein kinase. Cell Metab.
2011, 14, 707–714. [CrossRef]
67. Sugden, C.; Crawford, R.M.; Halford, N.G.; Hardie, D.G. Regulation of spinach SNF1-related (SnRK1) kinases by protein kinases
and phosphatases is associated with phosphorylation of the T loop and is regulated by 5′-AMP. Plant J. 1999, 19, 433–439.
[CrossRef]
68. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulin-dependent
protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2, 9–19. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 186 26 of 30
69. Woods, A.; Dickerson, K.; Heath, R.; Hong, S.P.; Momcilovic, M.; Johnstone, S.R.; Carlson, M.; Carling, D. Ca2+/calmodulin-
dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2,
21–33. [CrossRef]
70. Hurley, R.L.; Anderson, K.A.; Franzone, J.M.; Kemp, B.E.; Means, A.R.; Witters, L.A. The Ca2+/calmoldulin-dependent protein
kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 2005, 280, 29060–29066. [CrossRef]
71. Hawley, S.A.; Selbert, M.A.; Goldstein, E.G.; Edelman, A.M.; Carling, D.; Hardie, D.G. 5′-AMP activates the AMP-activated
protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent
mechanisms. J. Biol. Chem. 1995, 270, 27186–27191. [CrossRef] [PubMed]
72. Stahmann, N.; Woods, A.; Carling, D.; Heller, R. Thrombin activates AMP-activated protein kinase in endothelial cells via a
pathway involving Ca2+/calmodulin-dependent protein kinase kinase beta. Mol. Cell. Biol. 2006, 26, 5933–5945. [CrossRef]
[PubMed]
73. Stahmann, N.; Woods, A.; Spengler, K.; Heslegrave, A.; Bauer, R.; Krause, S.; Viollet, B.; Carling, D.; Heller, R. Activation
of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of
nitric-oxide synthase. J. Biol. Chem. 2010, 285, 10638–10652. [CrossRef] [PubMed]
74. Yang, Y.; Atasoy, D.; Su, H.H.; Sternson, S.M. Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent
positive feedback loop. Cell 2011, 146, 992–1003. [CrossRef]
75. Hardie, D.G. AMP-activated protein kinase: Maintaining energy homeostasis at the cellular and whole-body levels. Annu. Rev.
Nutr. 2014, 34, 31–55. [CrossRef]
76. Fu, X.; Wan, S.; Lyu, Y.L.; Liu, L.F.; Qi, H. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation.
PLoS ONE 2008, 3, e2009. [CrossRef]
77. Sanli, T.; Rashid, A.; Liu, C.; Harding, S.; Bristow, R.G.; Cutz, J.C.; Singh, G.; Wright, J.; Tsakiridis, T. Ionizing radiation activates
AMP-activated kinase (AMPK): A target for radiosensitization of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78,
221–229. [CrossRef]
78. Luo, L.; Huang, W.; Tao, R.; Hu, N.; Xiao, Z.X.; Luo, Z. ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to
etoposide-induced apoptosis. Cancer Lett. 2013, 328, 114–119. [CrossRef]
79. Sapkota, G.P.; Deak, M.; Kieloch, A.; Morrice, N.; Goodarzi, A.A.; Smythe, C.; Shiloh, Y.; Lees-Miller, S.P.; Alessi, D.R. Ionizing
radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. Biochem. J.
2002, 368 Pt 2, 507–516. [CrossRef]
80. Boudeau, J.; Baas, A.F.; Deak, M.; Morrice, N.A.; Kieloch, A.; Schutkowski, M.; Prescott, A.R.; Clevers, H.C.; Alessi, D.R. MO25a/b
interact with STRADa/b enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 2003, 22, 5102–5114.
[CrossRef]
81. Imamura, K.; Ogura, T.; Kishimoto, A.; Kaminishi, M.; Esumi, H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP
activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-d- ribofuranoside, in a human hepatocellular
carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 287, 562–567. [CrossRef] [PubMed]
82. Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase
induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18, 283–293. [CrossRef] [PubMed]
83. Winder, W.W.; Hardie, D.G. The AMP-activated protein kinase, a metabolic master switch: Possible roles in Type 2 diabetes. Am.
J. Physiol. 1999, 277, E1–E10. [CrossRef] [PubMed]
84. Henin, N.; Vincent, M.F.; Gruber, H.E.; Van den Berghe, G. Inhibition of fatty acid and cholesterol synthesis by stimulation of
AMP-activated protein kinase. FASEB J. 1995, 9, 541–546. [CrossRef] [PubMed]
85. Sullivan, J.E.; Brocklehurst, K.J.; Marley, A.E.; Carey, F.; Carling, D.; Beri, R.K. Inhibition of lipolysis and lipogenesis in isolated rat
adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994, 353, 33–36. [CrossRef]
86. Corton, J.M.; Gillespie, J.G.; Hawley, S.A.; Hardie, D.G. 5-Aminoimidazole-4-carboxamide ribonucleoside: A specific method for
activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 1995, 229, 558–565. [CrossRef] [PubMed]
87. Gadalla, A.E.; Pearson, T.; Currie, A.J.; Dale, N.; Hawley, S.A.; Sheehan, M.; Hirst, W.; Michel, A.D.; Randall, A.; Hardie, D.G.;
et al. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in
the CA1 region of the rat hippocampus. J. Neurochem. 2004, 88, 1272–1282. [CrossRef]
88. Hawley, S.A.; Ross, F.A.; Russell, F.M.; Atrih, A.; Lamont, D.J.; Hardie, D.G. Mechanism of activation of AMPK by cordycepin.
Cell Chem. Biol. 2020, 27, 214–222. [CrossRef]
89. Longnus, S.L.; Wambolt, R.B.; Parsons, H.L.; Brownsey, R.W.; Allard, M.F. 5-Aminoimidazole-4-carboxamide 1-beta -D-
ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am. J. Physiol. 2003, 284, R936–R944.
90. Vincent, M.F.; Marangos, P.J.; Gruber, H.E.; Van den Berghe, G. Inhibition by AICA riboside of gluconeogenesis in isolated rat
hepatocytes. Diabetes 1991, 40, 1259–1266. [CrossRef]
91. Foretz, M.; Hebrard, S.; Leclerc, J.; Zarrinpashneh, E.; Soty, M.; Mithieux, G.; Sakamoto, K.; Andreelli, F.; Viollet, B. Metformin
inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J.
Clin. Invest. 2010, 120, 2355–2369. [CrossRef] [PubMed]
92. Hunter, R.W.; Hughey, C.C.; Lantier, L.; Sundelin, E.I.; Peggie, M.; Zeqiraj, E.; Sicheri, F.; Jessen, N.; Wasserman, D.H.; Sakamoto, K.
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat. Med. 2018, 24, 1395–1406.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 186 27 of 30
93. Racanelli, A.C.; Rothbart, S.B.; Heyer, C.L.; Moran, R.G. Therapeutics by cytotoxic metabolite accumulation: Pemetrexed causes
ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009, 69, 5467–5474. [CrossRef]
[PubMed]
94. Pirkmajer, S.; Kulkarni, S.S.; Tom, R.Z.; Ross, F.A.; Hawley, S.A.; Hardie, D.G.; Zierath, J.R.; Chibalin, A.V. Methotrexate promotes
glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes 2015, 64, 360–369. [CrossRef]
95. Gomez-Galeno, J.E.; Dang, Q.; Nguyen, T.H.; Boyer, S.H.; Grote, M.P.; Sun, Z.; Chen, M.; Craigo, W.A.; van Poelje, P.D.;
MacKenna, D.A.; et al. A potent and selective AMPK activator that inhibits de novo lipogenesis. ACS Med. Chem. Lett. 2010, 1,
478–482. [CrossRef]
96. Langendorf, C.G.; Ngoei, K.R.; Scott, J.W.; Ling, N.X.; Issa, S.M.; Gorman, M.A.; Parker, M.W.; Sakamoto, K.; Oakhill, J.S.;
Kemp, B.E. Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding. Nat.
Commun. 2016, 7, 10912. [CrossRef]
97. Hunter, R.W.; Foretz, M.; Bultot, L.; Fullerton, M.D.; Deak, M.; Ross, F.A.; Hawley, S.A.; Shpiro, N.; Viollet, B.; Barron, D.; et al.
Mechanism of action of compound-13: An alpha1-selective small molecule activator of AMPK. Chem. Biol. 2014, 21, 866–879.
[CrossRef]
98. Tuli, H.S.; Sharma, A.K.; Sandhu, S.S.; Kashyap, D. Cordycepin: A bioactive metabolite with therapeutic potential. Life Sci. 2013,
93, 863–869. [CrossRef]
99. Wong, Y.Y.; Moon, A.; Duffin, R.; Barthet-Barateig, A.; Meijer, H.A.; Clemens, M.J.; de Moor, C.H. Cordycepin inhibits protein
synthesis and cell adhesion through effects on signal transduction. J. Biol. Chem. 2010, 285, 2610–2621. [CrossRef]
100. Guo, P.; Kai, Q.; Gao, J.; Lian, Z.Q.; Wu, C.M.; Wu, C.A.; Zhu, H.B. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat
diet via activation of AMP-activated protein kinase. J. Pharmacol. Sci. 2010, 113, 395–403. [CrossRef]
101. Tsou, P.; Zheng, B.; Hsu, C.H.; Sasaki, A.T.; Cantley, L.C. A fluorescent reporter of AMPK activity and cellular energy stress. Cell
Metab. 2011, 13, 476–486. [CrossRef] [PubMed]
102. Sazanov, L.A. A giant molecular proton pump: Structure and mechanism of respiratory complex I. Nat. Rev. Mol. Cell Biol. 2015,
16, 375–388. [CrossRef] [PubMed]
103. Shitan, N. Secondary metabolites in plants: Transport and self-tolerance mechanisms. Biosci. Biotechnol. Biochem. 2016, 80,
1283–1293. [CrossRef] [PubMed]
104. Mooney, M.H.; Fogarty, S.; Stevenson, C.; Gallagher, A.M.; Palit, P.; Hawley, S.A.; Hardie, D.G.; Coxon, G.D.; Waigh, R.D.;
Tate, R.J.; et al. Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. Br. J. Pharmacol.
2008, 153, 1669–1677. [CrossRef]
105. Parkinson, J. Galega, Goat’s Rue. In Theatricum Botanicum; Thomas Cotes: London, UK, 1640; pp. 417–418.
106. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of
the mitochondrial respiratory chain. Biochem. J. 2000, 348, 607–614. [CrossRef]
107. El-Mir, M.Y.; Nogueira, V.; Fontaine, E.; Averet, N.; Rigoulet, M.; Leverve, X. Dimethylbiguanide inhibits cell respiration via an
indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275, 223–228. [CrossRef]
108. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al. Role of
AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108, 1167–1174. [CrossRef]
109. Rena, G.; Hardie, D.G.; Pearson, E.R. The mechanisms of action of metformin. Diabetologia 2017, 60, 1577–1585. [CrossRef]
110. Zhang, C.S.; Li, M.; Ma, T.; Zong, Y.; Cui, J.; Feng, J.W.; Wu, Y.Q.; Lin, S.Y.; Lin, S.C. Metformin activates AMPK through the
lysosomal pathway. Cell Metab. 2016, 24, 521–522. [CrossRef]
111. Hardie, D.G. Regulation of AMP-activated protein kinase by natural and synthetic activators. Acta Pharm. Sin. B 2016, 6, 1–19.
[CrossRef]
112. Turner, N.; Li, J.Y.; Gosby, A.; To, S.W.; Cheng, Z.; Miyoshi, H.; Taketo, M.M.; Cooney, G.J.; Kraegen, E.W.; James, D.E.;
et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I:
A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57,
1414–1418. [CrossRef] [PubMed]
113. Huang, S.L.; Yu, R.T.; Gong, J.; Feng, Y.; Dai, Y.L.; Hu, F.; Hu, Y.H.; Tao, Y.D.; Leng, Y. Arctigenin, a natural compound, activates
AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice.
Diabetologia 2012, 55, 1469–1481. [CrossRef] [PubMed]
114. Hawley, S.A.; Ross, F.A.; Chevtzoff, C.; Green, K.A.; Evans, A.; Fogarty, S.; Towler, M.C.; Brown, L.J.; Ogunbayo, O.A.; Evans,
A.M.; et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010,
11, 554–565. [CrossRef] [PubMed]
115. Sharma, A.; Anand, S.K.; Singh, N.; Dwivedi, U.N.; Kakkar, P. Berbamine induced AMPK activation regulates mTOR/SREBP-1c
axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells. Eur. J. Pharmacol. 2020, 882,
173244. [CrossRef]
116. Li, J.; Liu, M.; Yu, H.; Wang, W.; Han, L.; Chen, Q.; Ruan, J.; Wen, S.; Zhang, Y.; Wang, T. Mangiferin improves hepatic lipid
metabolism mainly through its metabolite-norathyriol by modulating SIRT-1/AMPK/SREBP-1c signaling. Front. Pharmacol. 2018,
9, 201. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 186 28 of 30
117. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; et al. Identification
and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic
syndrome. Cell Metab. 2006, 3, 403–416. [CrossRef]
118. Goransson, O.; McBride, A.; Hawley, S.A.; Ross, F.A.; Shpiro, N.; Foretz, M.; Viollet, B.; Hardie, D.G.; Sakamoto, K. Mechanism
of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 2007, 282, 32549–32560.
[CrossRef]
119. Sanders, M.J.; Ali, Z.S.; Hegarty, B.D.; Heath, R.; Snowden, M.A.; Carling, D. Defining the mechanism of activation of AMP-
activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 2007, 282,
32539–32548. [CrossRef]
120. Scott, J.W.; van Denderen, B.J.; Jorgensen, S.B.; Honeyman, J.E.; Steinberg, G.R.; Oakhill, J.S.; Iseli, T.J.; Koay, A.; Gooley, P.R.;
Stapleton, D.; et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes.
Chem. Biol. 2008, 15, 1220–1230. [CrossRef]
121. Zadra, G.; Photopoulos, C.; Tyekucheva, S.; Heidari, P.; Weng, Q.P.; Fedele, G.; Liu, H.; Scaglia, N.; Priolo, C.; Sicinska, E.; et al.
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol. Med. 2014, 6, 519–538.
[CrossRef]
122. Esquejo, R.M.; Salatto, C.T.; Delmore, J.; Albuquerque, B.; Reyes, A.; Shi, Y.; Moccia, R.; Cokorinos, E.; Peloquin, M.; Mon-
etti, M.; et al. Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate
preclinical models. EBioMedicine 2018, 31, 122–132. [CrossRef] [PubMed]
123. Salatto, C.T.; Miller, R.A.; Cameron, K.O.; Cokorinos, E.; Reyes, A.; Ward, J.; Calabrese, M.; Kurumbail, R.; Rajamohan, F.;
Kalgutkar, A.S.; et al. Selective activation of AMPK b1-containing isoforms improves kidney function in a rat model of diabetic
nephropathy. J. Pharmacol. Exp. Ther. 2017, 361, 303–311. [CrossRef] [PubMed]
124. Cokorinos, E.C.; Delmore, J.; Reyes, A.R.; Albuquerque, B.; Kjobsted, R.; Jorgensen, N.O.; Tran, J.L.; Jatkar, A.; Cialdea, K.;
Esquejo, R.M.; et al. Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human primates
and mice. Cell Metab. 2017, 25, 1147–1159. [CrossRef] [PubMed]
125. Calabrese, M.F.; Rajamohan, F.; Harris, M.S.; Caspers, N.L.; Magyar, R.; Withka, J.M.; Wang, H.; Borzilleri, K.A.; Sahasrabudhe,
P.V.; Hoth, L.R.; et al. Structural basis for AMPK activation: Natural and synthetic ligands regulate kinase activity from opposite
poles by different molecular mechanisms. Structure 2014, 22, 1161–1172. [CrossRef]
126. Langendorf, C.G.; Kemp, B.E. Choreography of AMPK activation. Cell Res. 2015, 25, 5–6. [CrossRef]
127. Reymond, P.; Farmer, E.E. Jasmonate and salicylate as global signals for defense gene expression. Curr. Opin. Plant Biol. 1998, 1,
404–411. [CrossRef]
128. Hawley, S.A.; Fullerton, M.D.; Ross, F.A.; Schertzer, J.D.; Chevtzoff, C.; Walker, K.J.; Peggie, M.W.; Zibrova, D.; Green, K.A.;
Mustard, K.J.; et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336, 918–922.
[CrossRef]
129. Pinkosky, S.L.; Scott, J.W.; Desjardins, E.M.; Smith, B.K.; Day, E.A.; Ford, R.J.; Langendorf, C.G.; Ling, N.X.Y.; Nero, T.L.; Loh, K.;
et al. Long-chain fatty acyl-CoA esters regulate metabolism via allosteric control of AMPK beta1 isoforms. Nat. Metab. 2020, 2,
873–881. [CrossRef]
130. Carling, D.; Zammit, V.A.; Hardie, D.G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty
acid and cholesterol biosynthesis. FEBS Lett. 1987, 223, 217–222. [CrossRef]
131. Clark, H.; Carling, D.; Saggerson, D. Covalent activation of heart AMP-activated protein kinase in response to physiological
concentrations of long-chain fatty acids. Eur. J. Biochem. 2004, 271, 2215–2224. [CrossRef]
132. Suchankova, G.; Tekle, M.; Saha, A.K.; Ruderman, N.B.; Clarke, S.D.; Gettys, T.W. Dietary polyunsaturated fatty acids enhance
hepatic AMP-activated protein kinase activity in rats. Biochem. Biophys. Res. Commun. 2005, 326, 851–858. [CrossRef] [PubMed]
133. Watt, M.J.; Steinberg, G.R.; Chen, Z.P.; Kemp, B.E.; Febbraio, M.A. Fatty acids stimulate AMP-activated protein kinase and
enhance fatty acid oxidation in L6 myotubes. J. Physiol. 2006, 574 Pt 1, 139–147. [CrossRef]
134. Za’tara, G.; Bar-Tana, J.; Kalderon, B.; Suter, M.; Morad, E.; Samovski, D.; Neumann, D.; Hertz, R. AMPK activation by long chain
fatty acyl analogs. Biochem. Pharmacol. 2008, 76, 1263–1275. [CrossRef] [PubMed]
135. Hardie, D.G.; Carling, D. The AMP-activated protein kinase: Fuel gauge of the mammalian cell? Eur. J. Biochem. 1997, 246,
259–273. [CrossRef] [PubMed]
136. Yu, P.B.; Hong, C.C.; Sachidanandan, C.; Babitt, J.L.; Deng, D.Y.; Hoyng, S.A.; Lin, H.Y.; Bloch, K.D.; Peterson, R.T. Dorsomorphin
inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4, 33–41. [CrossRef] [PubMed]
137. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.; Alessi, D.R.; Cohen, P. The
selectivity of protein kinase inhibitors: A further update. Biochem. J. 2007, 408, 297–315. [CrossRef] [PubMed]
138. MRC Kinase Profiling Inhibitor Database. Available online: http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors (accessed on
30 September 2020).
139. Hemminki, A.; Markie, D.; Tomlinson, I.; Avizienyte, E.; Roth, S.; Loukola, A.; Bignell, G.; Warren, W.; Aminoff, M.; Hoglund, P.; et al.
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391, 184–187. [CrossRef]
140. Vara-Ciruelos, D.; Dandapani, M.; Hardie, D.G. AMP-activated protein kinase: Friend or foe in cancer? Annu. Rev. Cancer Biol.
2020, 4, 1–16. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 186 29 of 30
141. Sanchez-Cespedes, M.; Parrella, P.; Esteller, M.; Nomoto, S.; Trink, B.; Engles, J.M.; Westra, W.H.; Herman, J.G.; Sidransky, D.
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002, 62, 3659–3662.
142. Ji, H.; Ramsey, M.R.; Hayes, D.N.; Fan, C.; McNamara, K.; Kozlowski, P.; Torrice, C.; Wu, M.C.; Shimamura, T.; Perera, S.A.; et al.
LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448, 807–810. [CrossRef]
143. Lizcano, J.M.; Göransson, O.; Toth, R.; Deak, M.; Morrice, N.A.; Boudeau, J.; Hawley, S.A.; Udd, L.; Mäkelä, T.P.; Hardie, D.G.; et al.
LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J.
2004, 23, 833–843. [CrossRef] [PubMed]
144. Jaleel, M.; McBride, A.; Lizcano, J.M.; Deak, M.; Toth, R.; Morrice, N.A.; Alessi, D.R. Identification of the sucrose non-fermenting
related kinase SNRK, as a novel LKB1 substrate. FEBS Lett. 2005, 579, 1417–1423. [CrossRef] [PubMed]
145. Goodwin, J.M.; Svensson, R.U.; Lou, H.J.; Winslow, M.M.; Turk, B.E.; Shaw, R.J. An AMPK-independent signaling pathway
downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol. Cell 2014, 55, 436–450. [CrossRef]
[PubMed]
146. Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B.J.; Viollet, B.; et al. AMPK
Is a negative regulator of the Warburg effect and suppresses tumor growth In vivo. Cell Metab. 2012, 17, 113–124. [CrossRef]
[PubMed]
147. Houde, V.P.; Donzelli, S.; Sacconi, A.; Galic, S.; Hammill, J.A.; Bramson, J.L.; Foster, R.A.; Tsakiridis, T.; Kemp, B.E.; Grasso, G.;
et al. AMPK beta1 reduces tumor progression and improves survival in p53 null mice. Mol. Oncol. 2017, 11, 1143–1155. [CrossRef]
[PubMed]
148. Penfold, L.; Woods, A.; Muckett, P.; Nikitin, A.Y.; Kent, T.R.; Zhang, S.; Graham, R.; Pollard, A.; Carling, D. CAMKK2 promotes
prostate cancer independently of AMPK via increased lipogenesis. Cancer Res. 2018, 78, 6747–6761. [CrossRef] [PubMed]
149. Vara-Ciruelos, D.; Dandapani, M.; Russell, F.M.; Grzes, K.M.; Atrih, A.; Foretz, M.; Viollet, B.; Lamont, D.J.; Cantrell, D.A.;
Hardie, D.G. Phenformin, but not metformin, delays development of T cell acute lymphoblastic leukemia/lymphoma via
cell-autonomous AMPK activation. Cell Rep. 2019, 27, 690–698. [CrossRef]
150. Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic
patients. BMJ 2005, 330, 1304–1305. [CrossRef]
151. Decensi, A.; Puntoni, M.; Goodwin, P.; Cazzaniga, M.; Gennari, A.; Bonanni, B.; Gandini, S. Metformin and cancer risk in diabetic
patients: A systematic review and meta-analysis. Cancer Prev. Res. 2010, 3, 1451–1461. [CrossRef]
152. Huang, X.; Wullschleger, S.; Shpiro, N.; McGuire, V.A.; Sakamoto, K.; Woods, Y.L.; McBurnie, W.; Fleming, S.; Alessi, D.R.
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412, 211–221.
[CrossRef]
153. Crofford, O.B. Metformin. N. Engl. J. Med. 1995, 333, 588–589. [CrossRef] [PubMed]
154. Pineda, C.T.; Ramanathan, S.; Fon Tacer, K.; Weon, J.L.; Potts, M.B.; Ou, Y.H.; White, M.A.; Potts, P.R. Degradation of AMPK by a
cancer-specific ubiquitin ligase. Cell 2015, 160, 715–728. [CrossRef] [PubMed]
155. Vila, I.K.; Yao, Y.; Kim, G.; Xia, W.; Kim, H.; Kim, S.J.; Park, M.K.; Hwang, J.P.; Gonzalez-Billalabeitia, E.; Hung, M.C.; et al.
A UBE2O-AMPKalpha2 axis that promotes tumor initiation and progression offers opportunities for therapy. Cancer Cell 2017, 31,
208–224. [CrossRef] [PubMed]
156. Kishton, R.J.; Barnes, C.E.; Nichols, A.G.; Cohen, S.; Gerriets, V.A.; Siska, P.J.; Macintyre, A.N.; Goraksha-Hicks, P.; de Cubas, A.A.;
Liu, T.; et al. AMPK is essential to balance glycolysis and mitochondrial metabolism to control T-ALL cell stress and survival. Cell
Metab. 2016, 23, 649–662. [CrossRef]
157. Eichner, L.J.; Brun, S.N.; Herzig, S.; Young, N.P.; Curtis, S.D.; Shackelford, D.B.; Shokhirev, M.N.; Leblanc, M.; Vera, L.I.;
Hutchins, A.; et al. Genetic analysis reveals AMPK Is required to support tumor growth in murine Kras-dependent lung
cancer models. Cell Metab. 2019, 29, 285–302. [CrossRef]
158. Shackelford, D.B.; Abt, E.; Gerken, L.; Vasquez, D.S.; Seki, A.; Leblanc, M.; Wei, L.; Fishbein, M.C.; Czernin, J.; Mischel, P.S.; et al.
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell
2013, 23, 143–158. [CrossRef]
159. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al.
The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2,
401–404. [CrossRef]
160. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al.
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signal. 2013, 6, pl1. [CrossRef]
161. Monteverde, T.; Muthalagu, N.; Port, J.; Murphy, D.J. Evidence of cancer promoting roles for AMPK and related kinases. FEBS J.
2015, 282, 4658–4671. [CrossRef]
162. Phoenix, K.N.; Devarakonda, C.V.; Fox, M.M.; Stevens, L.E.; Claffey, K.P. AMPKalpha2 suppresses murine embryonic fibroblast
transformation and tumorigenesis. Genes Cancer 2012, 3, 51–62. [CrossRef]
163. Network, T.C.G.A.R. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511, 543–550.
164. Speidel, D. The role of DNA damage responses in p53 biology. Arch. Toxicol. 2015, 89, 501–517. [CrossRef] [PubMed]
165. Jung, J.W.; Park, S.B.; Lee, S.J.; Seo, M.S.; Trosko, J.E.; Kang, K.S. Metformin represses self-renewal of the human breast carcinoma
stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE 2011, 6, e28068. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 186 30 of 30
166. Bao, B.; Wang, Z.; Ali, S.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Banerjee, S.; Kong, D.; Li, Y.; Thakur, S.; et al. Metformin inhibits
cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer
cells. Cancer Prev. Res. 2012, 5, 355–364. [CrossRef] [PubMed]
167. Chen, X.; Hu, C.; Zhang, W.; Shen, Y.; Wang, J.; Hu, F.; Yu, P. Metformin inhibits the proliferation, metastasis, and cancer stem-like
sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol. 2015, 36, 9873–9883. [CrossRef]
168. Yuan, X.; Wei, W.; Bao, Q.; Chen, H.; Jin, P.; Jiang, W. Metformin inhibits glioma cells stemness and epithelial-mesenchymal
transition via regulating YAP activity. Biomed. Pharmacother. 2018, 102, 263–270. [CrossRef]
169. Saini, N.; Yang, X. Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta Biochim. Biophys.
Sin. 2018, 50, 133–143. [CrossRef]
170. Maehara, O.; Ohnishi, S.; Asano, A.; Suda, G.; Natsuizaka, M.; Nakagawa, K.; Kobayashi, M.; Sakamoto, N.; Takeda, H. Metformin
regulates the expression of CD133 through the AMPK-CEBPbeta pathway in hepatocellular carcinoma cell lines. Neoplasia 2019,
21, 545–556. [CrossRef]
171. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with
chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69, 7507–7511. [CrossRef]
172. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse
xenografts involving multiple cancer cell types. Cancer Res. 2011, 71, 3196–3201. [CrossRef]
173. Fasih, A.; Elbaz, H.A.; Huttemann, M.; Konski, A.A.; Zielske, S.P. Radiosensitization of pancreatic cancer cells by metformin
through the AMPK pathway. Radiat. Res. 2014, 182, 50–59. [CrossRef] [PubMed]
174. Vazquez-Martin, A.; Vellon, L.; Quiros, P.M.; Cufi, S.; Ruiz de Galarreta, E.; Oliveras-Ferraros, C.; Martin, A.G.; Martin-Castillo, B.;
Lopez-Otin, C.; Menendez, J.A. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogram-
ming somatic cells into stem cells. Cell Cycle 2012, 11, 974–989. [CrossRef] [PubMed]
175. Sato, A.; Sunayama, J.; Okada, M.; Watanabe, E.; Seino, S.; Shibuya, K.; Suzuki, K.; Narita, Y.; Shibui, S.; Kayama, T.; et al.
Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl. Med. 2012, 1, 811–824.
[CrossRef] [PubMed]
176. Bort, A.; Sanchez, B.G.; Mateos-Gomez, P.A.; Vara-Ciruelos, D.; Rodriguez-Henche, N.; Diaz-Laviada, I. Targeting AMP-activated
kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol. Oncol. 2019, 13, 1311–1331.
[CrossRef]
177. Sengupta, S.; Nagalingam, A.; Muniraj, N.; Bonner, M.Y.; Mistriotis, P.; Afthinos, A.; Kuppusamy, P.; Lanoue, D.; Cho, S.;
Korangath, P.; et al. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via
inhibition of oncogenic Stat3. Oncogene 2017, 36, 5709–5721. [CrossRef]
178. Wang, X.; Jin, J.; Wan, F.; Zhao, L.; Chu, H.; Chen, C.; Liao, G.; Liu, J.; Yu, Y.; Teng, H.; et al. AMPK Promotes SPOP-Mediated
NANOG Degradation to Regulate Prostate Cancer Cell Stemness. Dev. Cell 2019, 48, 345–360. [CrossRef]
179. Saito, Y.; Chapple, R.H.; Lin, A.; Kitano, A.; Nakada, D. AMPK protects leukemia-initiating cells in myeloid leukemias from
metabolic stress in the bone marrow. Cell Stem Cell 2015, 17, 585–596. [CrossRef]
